   
 
   
 COVER PAGE  
 
 
 
 
Official Study Title: NIRVANA: NIcotinamide Riboside in SARS -
CoV -[ADDRESS_506318] Number: NCT 04818216  
 
IRB Approval Date: 03.09.2021  
 
Protocol Number: HSC20200914H  
 
 
 
 
 
 
 
 
 
 
 
   
 NIRVANA: NIcotinamide Riboside in SARS -CoV -2 pAtients for 
reNAl protection  
 
Protocol Number: Pending  
National Clinical Trial (NCT) Identified Number:  Pending Registration  
Principal Investigator:  [INVESTIGATOR_401523], MD  
IND Sponsor: Kumar Sharma, MD  
IND Number: 152024  
Funded by: [CONTACT_401603] 
(NIDDK), the National Institutes of Health (NIH)   
Version Number:  v.1.0   
December 1 6, 2020  
 
 
Summary of Changes  from Previous Version:  
Affected 
Section(s)  Summary of Revisions Made  Rationale  
   
   
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
1 Table of Contents  
STATEMENT OF COMPLIANCE  ................................ ................................ ................................ .............................  3 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............................  4 
1.1 Synopsis  ................................ ................................ ................................ ................................ ................  4 
1.2 Schema  ................................ ................................ ................................ ................................ .................  6 
1.3 Schedule of Activities (SoA)  ................................ ................................ ................................ ...............  7 
2 INTRODUCTION  ................................ ................................ ................................ ................................ ............  8 
2.1 Study Rationale  ................................ ................................ ................................ ................................ .... 8 
2.2 Backgr ound ................................ ................................ ................................ ................................ .........  10 
2.3 Risk/Benefit Assessment  ................................ ................................ ................................ ..................  11 
2.3.1  Known Potential Risks  ................................ ................................ ................................ ... 11 
2.3.2  Known Potential Benefits  ................................ ................................ ..............................  15 
2.3.3  Assessment of Potential Risks and Benefits  ................................ ..............................  15 
3 OBJECTIVES AND ENDPOINTS  ................................ ................................ ................................ ..............  16 
4 STUDY DESIGN  ................................ ................................ ................................ ................................ ...........  18 
4.1 Overall Design  ................................ ................................ ................................ ................................ .... 18 
4.2 Scientific Rationale for Study Design ................................ ................................ ..............................  18 
4.3 Justification for Dose  ................................ ................................ ................................ .........................  19 
4.4 End of Study Definition  ................................ ................................ ................................ .....................  20 
5 STUDY POPULATION  ................................ ................................ ................................ ................................  20 
5.1 Inclusion Criteria  ................................ ................................ ................................ ................................  20 
5.2 Exclusion Criteria  ................................ ................................ ................................ ...............................  21 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ....................  22 
5.4 Screen Failures  ................................ ................................ ................................ ................................ .. 22 
5.5 Strategies for Recruitment and Retention  ................................ ................................ ......................  23 
6 STUDY INTERVENTION  ................................ ................................ ................................ ............................  25 
6.1 Study Intervention(s) Administration  ................................ ................................ ...............................  25 
6.1.1  Study Intervention Description  ................................ ................................ .....................  25 
6.1.2  Dosing and Administration  ................................ ................................ ............................  28 
6.2 Preparation/Handling/Storage/Accountability  ................................ ................................ ................  28 
6.2.1  Acquisition and accountability  ................................ ................................ ......................  28 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ................................ ................  29 
6.2.3  Produc t Storage and Stability  ................................ ................................ .......................  29 
6.2.4  Preparation  ................................ ................................ ................................ ......................  30 
6.3 Measures to Minimize Bias: Randomization and Blinding  ................................ ...........................  30 
6.4 Study Intervention Compliance  ................................ ................................ ................................ ........  31 
6.5 Concomitant Therapy  ................................ ................................ ................................ ........................  31 
6.5.1 Rescue Medicine  ................................ ................................ ................................ ............  31 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ................................ ....................  31 
7.1 Discontinuation of Study Intervention  ................................ ................................ .............................  31 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ ...............................  [ADDRESS_506319] to Follow -Up ................................ ................................ ................................ ...............................  33 
8 STUDY ASSESSMENTS AND PROCEDURES  ................................ ................................ .....................  34 
8.1 Efficacy Assessments  ................................ ................................ ................................ .......................  34 
8.2 Safety and Other Assessments  ................................ ................................ ................................ .......  38 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
2 8.3 Adverse Events and Serious Adverse Events  ................................ ................................ ...............  41 
8.3.1  Definition of Adverse Events (AE)  ................................ ................................ ...............  41 
8.3.2  Definition of Serious Adverse Events (SAE)  ................................ ..............................  [ADDRESS_506320]  ................................ ................................ .............................  48 
8.3.10  Reporting of Pregnancy  ................................ ................................ ................................  48 
8.4 Unanticipated Problems  ................................ ................................ ................................ ....................  48 
8.4.1  Definition of Unanticipated Problems (UP)  ................................ ................................ . 48 
8.4.2  Unanticipated Problem Reporting  ................................ ................................ ................  48 
8.4.3  Reporting Unanticipated Problems to Participants  ................................ ...................  49 
9 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ ..........  49 
9.1 Statistical Hypotheses  ................................ ................................ ................................ .......................  49 
9.2 Sample Size Determination  ................................ ................................ ................................ ..............  49 
9.3 Populations for Analyses  ................................ ................................ ................................ ..................  50 
9.4 Statistical Analyses ................................ ................................ ................................ ............................  50 
9.4.1  General Approach  ................................ ................................ ................................ ..........  50 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ................................ .............................  51 
9.4.3  Analysis of the Secondary Endpoint(s)  ................................ ................................ .......  [ADDRESS_506321] Policy  ................................ ................................ ..............................  66 
10.2  Additional Considerations  ................................ ................................ ................................ .................  66 
10.3  Abbreviations  ................................ ................................ ................................ ................................ ...... 67 
10.4  Protocol Amendment History  ................................ ................................ ................................ ...........  68 
11 REFERENCES  ................................ ................................ ................................ ................................ .............  69 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
3  
STATEMENT OF COMPLIANCE  
 
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 
Practice ( ICH GCP) and the following :  
 
• [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR 
Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312 , and/or 21 CFR Part 8 12)  
 
National Institutes of Health ( NIH)-funded investigato rs and clinical trial site staff who are 
responsible  for the conduct, management, or  oversight of NIH -funded clinical trials  have 
completed Human Subjects Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will 
be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both 
the protocol and the consent form must be obtained before any participant is enrolled.  Any 
amendment to the protocol will require review and approval by [CONTACT_52590].  In addition, a ll changes to the consent form will be IRB -approved; a 
determination will be made regarding whether  a new consent needs to be obtained from 
participants  who provided consent , using a previously approved consent form . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
4 1  PROTOCOL SUMMARY  
1.1 SYNOPSIS   
Title  NIcotinamide Riboside in SARS -CoV -2 pAtients for reNAl protection 
(NIRVANA)  
Study 
Description  A pi[INVESTIGATOR_2268], double -blind, placebo -controlled, multicenter, interventional clinical 
trial with oral nicotinamide riboside (NR) 500 mg (versus placebo) twice 
daily for a total of 10 days in hospi[INVESTIGATOR_401524] -19. 
Objectives  
 Primary  
• To determine the effect of nicotinamide riboside (NR) on whole blood 
NAD+ levels in hospi[INVESTIGATOR_41374] -19 infection and AKI 
during the 10 -day intervention period ; 
• To evaluate the safety of NR in patients with COVID -19 infection and 
AKI during the 10 -day intervention period ; 
Secondary  
• To determine the effect of NR on changes in  area under curve (AUC)  
serum creatinine from baseline during the 10 -day intervention ; 
• To determine the effects of NR on  serum creatinine AUC, dialysis, and 
death with an ordinal categorical outcome having four categories 
(labeled 1, 2, 3, 4), defined as, in order from least to most severe disease, 
1. Serum creatinine AUC < med ian, 2. Serum creatinine AUC ≥ median, 
3. Dialysis, 4. Death during the 90d period post randomization ;   
• To determine the effect of NR on MAKE (Major Adverse Kidney Events;  
composite  criteria defined as development or progression of chronic 
kidney disease , the initiation of long -term dialysis, or death from any 
cause ) at 30d and 90d post randomization ; 
• To determine the effect of NR on degree of kidney impairment defined 
with  estimated glomerular filtration rate (eGFR) and proteinuria  at 30d 
and 90d post randomization ; 
Exploratory  
• To determine the relationship of whole blood NAD+ levels with AUC 
creatinine and surrogate markers of AKI such as kidney injury molecule -
1 (KIM -1) and neutrophil gelatinase -associated lipocalin (NGAL);  
Endpoints  Primary  
• Rates of change in whole blood NAD+ level from baseline to day 10 in 
NR compared to Placebo.  
• Safety of NR in hospi[INVESTIGATOR_41374] -19 and AKI (defined as 
the occurrence of at least one serious adverse event of grade 3 or higher 
or the occurrence of thrombocytopenia (>25% decline i n blood platelet 
count from baseline value).  
 
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
5  
 
 
 
 
 
 Secondary  
• Rates of change in AUC serum creatinine benchmarked to baseline 
from baseline to day 10 in NR compared to Placebo;  
• An ordinal categorical outcome with four categories (labeled 1, 2, 3, 
4), defined as, in order from least to most severe disease, 1. Serum 
creatinine AUC < median, 2. Serum creatinine AUC ≥ median, 3. 
Dialysis, 4. Death;  
• Time to first occurrence of MAKE (doub ling of serum creatinine, the 
initiation of long -term dialysis, or death from any cause) at [ADDRESS_506322] randomization;  
• Kidney function defined by [CONTACT_401604] 30d and 90d 
post randomization . 
 
Exploratory  
• Correlations between whole blood NAD+, AUC serum creatinine, and 
AKI surrogate markers of AKI such as KIM -1 and NGAL;  
Study 
Population:  Participants will be >18 years old and admitted to hospi[INVESTIGATOR_4791] a 
laboratory diagnosis of COVID -19 infection and AKI  
Phase:  Phase 2  
Description of 
Sites/Facilities 
Enrolling 
Participants:  The study is a multicenter study with University of [LOCATION_007] Health San Antonio 
(UTHSA) as the coordinating site. The three recruiting sites are: University 
Hospi[INVESTIGATOR_401525], Icahn School o f Medicine at Mount Sinai, 
[LOCATION_001], NY and Harborview Medical Center/University of Washington, 
Seattle, WA  
Description of 
Study 
Intervention:  The intervention for this clinical trial is Niagen®, a nicotinamide riboside, 
an over the counter nutritional su pplement  
Study Duration  Estimated 2 years  
Participant 
Duration:  The estimated time required for this study will be up to 90 days after 
consenting to study protocol. A total of up to 10 visits will occur during the 
initial 10 days  with two follow -up visits – 30 days and 90 days from 
enrollment date.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
6 1.2 SCHEMA  
 
Flow diagram of the NIRVANA Study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
COVID, Corona virus disease; EHR, Electronic health records; NR, Nicotinamide Riboside  
    
 
   Total N=100:  Using EHRs screen potential participants by 
[CONTACT_156587]/exclusion criteria; obtain informed consent with COVID safety in 
place, document medical history.  
• Perform baseline assessments:  
⸰ Obtain vitals and physical examination data from EHRs  
⸰ Collect blood and urine  
• Administer initial study intervention: NR vs Placebo.  
 • Administer study intervention: NR vs Placebo.  
• Collect and assess study endpoints and safety  data 
• Collect blood and urine  
⸰ Perform laboratory safety assessments   
⸰ Perform whole blood NAD+ measurement   
 Placebo  n=50  
N =50  
participantsN 
participants   NR n=50  
N 
N = 50  
5participants
N participants  
  Randomize  Prior to  
Enrollment  
Baseline 
visit: Day 1  
Treatment 
visits:  
Day 1 -10 
(Daily)  
Follow -up 
visits:  
Day 30, 90  • Perform follow -up assessments:  
⸰ Vitals and physical examination  at d30 and d90  
• Collect urine and blood at d30 and d90  
• Collect and assess study endpoints and safety data  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
7 1.3  SCHEDULE OF ACTIVITIES (SOA)  
 APACHE -II, Acute physiology and chronic health evaluation II; AE, adverse events; ICU, Intensive care unit;  
* Baseline (Day 1) assessments should be performed prior to study drug administration;  
1 Includes all inhospi[INVESTIGATOR_401526] (standard of care treatment, prescri ption , over -the-counter, 
supplements);   
2Dosing of the first study drug will be administered as soon as possible (within [ADDRESS_506323] for women with childbearing potential);  
[ADDRESS_506324] hospi[INVESTIGATOR_5107] 10 intervention will be provided with study pi[INVESTIGATOR_401527] d ays.  
4 Respi[INVESTIGATOR_697], FiO 2, O 2 saturation, ventilator parameters, if applicable  and participant is hospi[INVESTIGATOR_057] ; 
[ADDRESS_506325] morning urine collections if discharged from hospi[INVESTIGATOR_307];  
6Any laboratory tests performed as part of routine clinical  care within the specified visit day may be used for safety 
laboratory testing  by [CONTACT_401605] ; Table 1. Schedules of activities  
Study Period  Scree
ning Treatment Period 
 Follow -up  
  
Visit Encounter  Visit 
0/ 
Day 
 0  Visit 
1/ 
Day 
1  
(Base
line)* Visit 
2/ 
Day 
2 Visit 
3/ 
Day 
3 Visit 
4/ 
Day 
4 Visit 
5/ 
Day 
5 Visit 
6/ 
Day 
6 Visit 
7/ 
Day 
7 Visit 
8/ 
Day 
8 Visit 
9/ 
Day 
9 Visit 
10/ 
Day 
10 Visit 
11/ 
Day 
30 ± 
3 Visit 
12/ 
Day 
90 
±3 Procedure  
Eligibility criteria X             
Informed consent  X             
Demography  X             
Medical history  X             
Concomitant 
medication s1 X X X X X X X X X X X X X 
Vital signs   X X X X X X X X X X X X 
Physical 
examination  X X X X X X X X X X X X X 
STUDY INTERVENTION  
Randomization2   X            
Study drug 
administration3  X X X X X X X X X X   
STUDY PROCEDURES  
APACHE -II X X X X X X X X X X X   
Endpoint 
assessment   X X X X X X X X X X X X 
AE assessment   X X X X X X X X X X X X 
Respi[INVESTIGATOR_401528]4  X X X X X X X X X X X   
Mortality, ICU 
transfer, length of 
stay X X X X X X X X X X X X X 
Urine output5  X X X X X X X X X X   
CLINICAL LABORATORY  
Blood analys is6  X X X X X X X X X X X⁋ X⁋ 
SAFETY LABORATORY 
Blood  analysis7  X X X X X X X X X X X X 
RESEARCH LABORATORY  and REPOSITORY  
Blood and urine8  X X X X X X X X X X X X 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
8 7 Creatine phosphokinase and liver function tests will be performed on Day 5  (see Table 4)  
8 Whole blood NAD+ and serum creatinine will be collected daily  before study medication dosing ; Blood will be 
collected at [ADDRESS_506326] -randomization for future pharmacokinetics;  Blood and urine for biomarkers 
will be collected at Baseline and daily during the inte rvention period, at day 30 ± 3 and day 90 ± 3;  
⁋If the participant is still hospi[INVESTIGATOR_401529]  
 
2  INTRODUCTION  
 
2.1 STUDY R ATIONALE   
 
Impaired mitochondrial function has been recently recognized as a major mechanism for acute 
kidney injury ( AKI) in septic shock and ischemia -reperfusion injury [1-5]. A major feature that 
limits mitochondrial function is the reduction of electron donors to the mitochondria in the form 
of nicotinamide adenine dinucleotide (NAD+). Reduced levels of NAD+ have been implicated in 
both animal models and humans with AKI, and stimulation of pathways that lead to 
enhancement of NAD + appears to be beneficial [3, 4, 6] . Recent studies using oral nicotinamide 
(NAM) and nicotin amide riboside (NR) as NAD+ donors have found these agents to be safe, 
well-tolerated, and upregulate NAD+ pathways in a dose -dependent manner [7, 8] . NR provided 
after  organ injury was found  to be protective  in pre -clinical studies [9, 10] . It has been 
demonstrated t hat NR is more orally bioavailable than NAM, safe in obese participants , and 
beneficial  in many pre -clinical models of organ dysfunction [7, 8, 11 -14]. NAM use during the 
perioperative period in participants undergoing cardiothoracic surgery showed reduced incidence 
of AKI in a pi[INVESTIGATOR_799] [5]. NR use  (in comb ination with pterostilbene , PT; NRPT ) was found to 
increase NAD+ levels in patients with AKI as compared to the p lacebo group [15]. 
 
The kidneys are highly active metabolically, contain a high density of mitochondria , and 
consume the highest amount of oxygen after the heart. Mitochondrial energy (adenosine 
triphosphate or ATP) production requires the universal cofactor nicotinamide adenine 
dinucleotide (NAD). This essential metabo lite serves as a key cofactor in a plethora of 
mitochondrial metabolic processes that facilitate energy production as well as several other 
important cellular functions [16]. Consisten t with these key roles of NAD+, various stress ors 
have been associated with decreased NAD+ levels  [15], contributing to disease pathogenesis.  
 
Rationale for Study Design:  
We chose a treatment protocol with NR  as a treatment  for patients who will be admitted with 
COVID -19 related illness and develop AKI after admission. Treatment duration will be for 10 
days and the primary study endpoint will be  the change in whole blood NAD+ from bas eline  (to 
10d, 2d, AUC)  in NR group vs placebo group.  We will evaluate  whole blood NAD+ levels  as a 
marker of efficacy  and biological effect  of  NR based on two recent publications [8, 15] . We 
evaluated using a marker of efficacy for NR with the whole blood NAD+ based on two recent 
publications [8, 15]. In a study of healthy o verweight subjects 40 -60 years of age, Conze et al. 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
9 [8] found a 21 µg/ml mean NAD+ difference between patients randomized to 1000 mg 
NIAGEN® versus those randomized to placebo at day 7 (NIAGEN 42 µg/ml, Placebo 21 µg/ml) 
with a standard deviation of 10 µg/ ml and approximately equal baseline means (NIAGEN 21 
µg/ml, Placebo 24 µg/ml).  Simic et al. [15] assessed a combination of NR with pterostilbene 
(NRPT) vs placebo in hospi[INVESTIGATOR_401530] ≥ 18 years with AKI and found an 18% 
increase in whole blood  NAD+ within 48h post treatment in the NRPT group, and a 50% 
reduction from baseline in the placebo group with AKI. With reference to Conze et al. [8] al., 
this study will achieve >99.9% power for testing H o:RNR = R Placebo  versus Ho: R NR≠RPlacebo  with 
alpha=0.05, autocorrelation ( )=0.5, and n=[ADDRESS_506327] to NAD+.  In this setting the effect 
size is 2.1 [=(42 -21)/10] and the minimally detectable effect size is 0.63.    
Safety of NR will also be assessed as a primary endpoint in this study. Although NR is generally 
recognized as safe or GRAS  [17] and has been demonstrated to be well -tolerated with mild, if 
any side effects , reported using variables doses from 100 mg/day up to 2000 mg/day [8, 11, 12]  it 
will be informative to assure that serious adverse events (SAEs) are not increased with NR in 
patients with  COVID -19 infection and AKI.  
 
We also plan to assess the AUC of serum creatinine benchmarked to baseline and other clinical 
outcomes as secondary endpoints to determine if there are trends indicating that NR may be a 
promising treatment for hospi[INVESTIGATOR_60992] -19 infected patients who develop AKI. We will 
also correlate whole blood NAD+ levels with AUC creatinine with well described surrogate 
markers of AKI (KIM -1, NGAL) as an exploratory outcome measure. If we demonstrate that NR 
increases whole blood NAD+ in COVID -19 positive patients with AKI  and is safe , this result 
would be a compelling finding to support further clinical trials with NR in this population. 
Further support for future studies would be obtained from our secondary endpoints and will of 
great value in establishing power calculations for future definitive studies  [9, 10] . 
 
Upon completion of the NRIVANA study , we plan to pursue a Phase IIb or Phase III study based 
on the following  scenarios :    
 
1. Demonstrate significant increase in whole blood NAD+ level in the NR group compared 
to placebo (p<0.05), no significant increase in harm with NR treatment and a positive 
trend or improvement in any one of the secondary outcomes (p<0.2) would warrant a 
future Phase III study.  
2. Demonstrate significant increase in whole blood NAD+ level in the NR group compared 
to placebo (p<0.05) and no significant increase in harm with NR treatment would warrant 
a Phase IIb study.  
3. Demonstrate significant improvement in any one of the secondary outcomes with NR 
compared to place bo (p<0.2) and no significant increase in harm with NR treatment 
would warrant a Phase IIb study.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
10  
In a future Phase III clinical trial, we envision the primary endpoint would be the MAKE (Major 
Adverse Kidney Events) – the proportion of subjects who deve lop any of the components of 
MAKE at d90 post randomization. In the NIRVANA study MAKE is one of the secondary 
endpoints.     
 
2.2 BACKGROUND   
 
Severe acute respi[INVESTIGATOR_6507] 2 (SARS -CoV -2), the causative agent of the 
novel coronavirus 2019 disease (COVID -19), is responsible for the global pandemic which is 
taking a tremendous toll in the form of human morbidity and mortality. SARS -CoV -2 infection 
is unpredictable in its course as it may be asymptomatic in some patients but rapi[INVESTIGATOR_401531]-threatening complications in others leading to multisystem organ failure [18-21]. Kidney 
involvement is prominent in admitted patients with COVID -19 pneumonia with 75% exhibiting 
proteinuria, hematuria, or AKI [22]. In a comprehensive analysis of 5,449 patients admitted with 
COVID -19, AKI developed in 1,993 patients for an incidence rate of 37% [23]. The incidence of 
AKI is even higher (68%) in COVID -19 patients admitted to the intensive care unit (ICU) as 
reported from [LOCATION_001] City [24]. Moreover, up to 86% of deaths in COVID -19 patients were 
associated with AKI [22]. The overall mortality in hospi[INVESTIGATOR_60992] -19 infected patients was 
originally found to be 25.6% however more recent studies find the mo rtality rate to be now at 
about 7 .6% [25]. The basis for AKI with COVID -19 is not known.  The N3C database, as of 18 
November 2020, indicated that of 1213 hospi[INVESTIGATOR_60992] -19 patients with AKI satisfying our  
entry criteria and not satisfying our exclusion criteria, a total of 120 (9.9%) died. The actual 
dates of death are not known . 
 
The pathophysiology of AKI is multifactorial, and, in many cases, the precise mechanism of AKI 
is unclear [26, 27] . Currently there is scar city of data with regard to the underlying pathogenesis 
of AKI in SARS -CoV -2 patients. However, the “cytokine storm” appears to be the primary 
contributing factor to AKI and disease severity in patients with COVID -19 [28, 29] . Based on 
clinical observations, AKI occurs in critically ill patients with COVID -19 that are under severe 
metabolic stress originating from maladaptive systemic inflammat ory immune response, 
hypoxemia, ischemia, microthrombi, sepsis, and toxins (e.g., rhabdomyolysis) [28]. The kidneys 
may also be the site for direct invasion of SARS -CoV -2 due to the high ex pression of ACE2 in 
renal tubular epi[INVESTIGATOR_018] [30, 31] . Therefore, it is possible that inflammatory events and/or direct 
SARS -CoV -2 infection of re nal cells lead to a metabolic derangement affecting the NAD+ 
metabolome and consequent mitochondrial dysfunction leading to AKI. At the present time there 
is no targeted treatment for AKI. Given the role of mitochondrial function and NAD+ in other 
models o f AKI and multi -organ failure associated with infection and inflammation, we postulate 
that a similar process of reduced NAD+ and reduced mitochondrial function may underlie AKI 
with COVID -19 infection.  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
11 NR and NAD restoration in animal studies of organ injury  
Mice receiving intraperitoneal administration of NR at 185 mg /kg for 6 days had about 100 -fold 
increase in nicotinic acid adenine dinucleotide in the heart [32]. Another study also demonstrated 
that mice with NR administration  of 400 mg compound/kg body weight per day caused increase 
of NAD+ levels in muscle and liver [33]. Interventional studies also showed  beneficial effects of 
NR on specific organ injury. NR significantly reduced non -fasting and fasting blood glucose, 
weight gain and hepatic steatosis and protected neuropathy in diabetic mice supplemented with 3 
g of NR per kg of their diet [32]. A study in rats of intestinal ischemia -reperfusion found that 
administration of NR (50 mg/kg) at end of ischemia period and early reperfusion led to 
endothelial protection and intestinal wall protection from reperfusion injury [9]. NR 
supplementation to murine models of dilated cardiomyopathy or heart failure restores myocardial 
NAD levels and preserves cardiac function via in duction of the nicotinamide riboside kinase 2 
(NMRK2 ) pathway for NAD+ synthesis [10]. Others also demonstrated that NR can prevent 
alcohol or non -alcohol induced l iver injuries via replenishing NAD+, reducing oxidative stress, 
activating S IRT1-PGC -1α-mitochondrial biosynthesis or sirtuin (SIRT)1 - and SIRT 3-dependent 
mitochondrial unfolded protein response [34-36]. 
 
Therefore, a therapeutic to safely restore mitochondrial function  in patients with recent onset 
AKI may be of major benefit to reduce the severity of AKI in newly admitted patients with 
COVID -19. We specifically hypothesize that supplementation with NR will reduce  the severity 
of AKI in newly admitted SARS -CoV -2 patients.  
 
2.3 RISK/BENEFIT ASSESSMENT    
   
2.3.[ADDRESS_506328] of care to prevent or treat AKI.  
As with any research study, there is a po tential for side effects to occur with the administration of 
the study drug. All participants will be closely monitored on a daily basis for adverse events 
(AEs) defined as changes in health condition and laboratory parameters from baseline (Day 1). 
Few side effects have been identified for the use of NR, but the side effects that have been 
reported such as nausea, back soreness and muscle soreness have been typi[INVESTIGATOR_401532] [8].  
 
NR is a formal precursor of NAD+ and naturally present in certain foods including milk. After 
absorption, NR enters the cell, and is metabolized into nicotinamide mononucleotide (NMN) by 
a phosphorylation step catalyzed by [CONTACT_401606]  (NRKs). NMN is 
subsequently converted to NAD by [CONTACT_401607] (NMNAT1 -3). 
However, the quantities in foods are quite low, and probably do not exceed the low micromolar 
range [37]. In the [LOCATION_003], NR is considered as GRAS or Generally Recognized as Safe for use in 
food products which supports its rapid implementation as a drug -like therapy [17].  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
12 NR has been demonstrated to be well -tolerated with mild, if any side effects reported using 
variables doses from 100 mg/day up to 2000 mg/day [8, 11, 12] . The current study intervention 
is 1000 mg/day administered  as 500 mg twice a day.  
 
NR was recently evaluated in a single center, double blind, placebo -controlled, and crossover  
study in which 12 elderly participants received 500 mg NR twice a day for 21 days . In this study  
NR was well tolerated without any SAE  including no changes in hematological and clinical 
biochemistry safety parameters – i.e., renal, liver, and thyroid functions [14].  The reported 
symptoms included nausea, flushing, leg cramps and increased bruising in the NR group  and 
headache, skin rash, flushing, fainting and drowsiness in the placebo group  [7].  
 
A dose escalation study was performed in 8 healthy subjects in a non -randomized, open -label 
pharmacokinetic s (PK) study with 250 mg NR orally administered on days 1 and 2, then 
uptitrated to peak dose of 1000 mg twice daily on days 7 and 8. No clinically s ignificant changes 
were seen at NR dose up to 1000 mg orally twice daily in any of the five pre -specified safety 
endpoints, i.e., potassium, creatine phospho kinase  (CPK) , glucose, uric acid and alanine 
aminotransferase. Serum potassium decreased by [CONTACT_401608] 0.4 mEq/L, which was 
statistically significant (p = 0.015) but the individual levels remain in normal range. There was a 
slight though statistically significant decrease for hematocrit (mean difference = −2%, p = 
0.005), hemoglobin ( -0.4 g/dL, p = 0 .04), and platelet count ( -20,000/μL, p = 0.03). There were 
no significant changes in blood pressure, body temperature, body weight, white blood cell count, 
lactate dehydrogenase or aspartate aminotransferase. In addition, there were no significant 
changes  in serum levels of sodium, chloride, urea nitrogen, creatinine, or in white blood cell 
differential [38].  
 
In an investigator -initiated randomized, placebo -controlled, double -blinded study of 40 healthy 
men with BMI> 30 kg/m2 NR was administered at a dose of 1000mg twice daily for 12 weeks 
[39]. Adverse events ( AEs) were reported in 4 subjects in the NR group which included pruritis, 
excessive sweating, bloating and transient changes in stool. There were two AEs in the placebo 
group which were acid reflux and loose stools. The severity was mild in all cases. Laborator y 
analysis for blood counts and chemistries at 6 weeks revealed no abnormalities in the NR group.  
 
A recent report evaluated a combination of NR with an anti -oxidant pterostilbene (PT; NRPT) in 
24 hospi[INVESTIGATOR_401533] a single dose ranging from 250mg NR, 500mg NR, 
750mg NR to 1000mg NR twice a day [15]. Compared to the baseline timepoint, NRPT dose 500 
mg/100 mg twice  a day increased  whole blood NAD+ levels 47% at 48 h, (p = 0.04). Whole 
blood NAD+ levels in patients with AKI receiving placebo decreased by 50% at 48 h (p = 0.05). 
Compared to placebo, there was no significant difference in creatinine, estimated glomerular 
filtration rate ( eGFR ), electrolytes (sodium, potassium), liver enzymes (ALT, AST, ALP), 
hemoglobin, white blood count or platelet count in patients treated with NRPT at 48 h. NRPT 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
13 was safe at all doses in patients with AKI with only minor side effects (bl oating and gas, upper 
abdominal discomfort) reported that resolved without intervention. There were no side effects in 
placebo group. There was no SAE in either group [15]. 
 
Safety of NRPT (u p to 500 mg NR + 100 mg PT/day) has also been evaluated in a randomized, 
placebo -controlled , double -blind study in a population of 120 healthy adults between the ages of 
60 and 80 years  for 8 weeks [40]. There was a total of six AEs – nausea, fatigue, headache, 
dyspepsia, abdom inal discomfort, and diarrhea with mil d to moderate intensity.  
  
In the largest study to date, 140 healthy male and female participants (40 -60 years of age) 
underwent a randomized, placebo -controlled  study with 4 groups: placebo (n=35), 100 mg group 
(n=35), 300mg/d (n=35) and 1000mg/d (n=35) and supplementation was prov ided for 56 d [8]. 
One subject in placebo group dropped out due to nausea, one subject was withdrawn from [ADDRESS_506329] to follow -up. Compliance 
ranged from 97.1% -99% across all groups. There were no serious adverse events ( SAEs ) and the 
type, incidence and severity of the AEs were similar across all groups – 17 participants in 
placebo group, 16 in 100 mg/d group, 14 in 300mg/d group a nd 14 in 1000mg/d group. There 
were a total of 22 AEs in the 1000mg NR group with 3 being reported as possibly related to 
study drug: sore back, muscle soreness , and nausea with mild in intensity. Hematological and 
chemistry profiles were similar in all gr oups.  The effects of NR on muscle metabolism has been 
studied [14, 33] ; however, these studies did not measure serum  cystatin C  or CPK . 
 
There are paucity of data regarding the s afety profile of NR in patients with CKD. T wo clinical 
trials of NR in patie nts with eGFR 20 -60 mL/min/1.73m2 are ongoing  [41, 42] . Forms of vitamin 
B3 nicotinic acid (pyridine -3-carboxylic acid  or niacin ) and its circulating amide derivative 
nicotinamide (pyridine -3-carboxamide , NAM )  have been tested in advanced CKD patients 
undergoing  hemo - and peritoneal dialysis patients [43]. One randomized, placebo -controlled 
clinical trial tested NAM (750 mg twice daily) alone and in combination with lanthanum 
carbonate among individuals with eGFR 20 –45 ml/min per 1.73 m2 for 12 months [44]. This 
study reported severe nausea, severe diarrhea, flushing, hives, bruising  and bleeding in the NAM 
group (n=51) which were not significantly different than that reported in the placebo group with 
the exception of hives. It is important to note that this particular study did not f ind any evidence 
of thrombocytopenia (platelet cou nt <100,000/mm2), liver function abnormalities, and elevated 
CPK  (>800 U/L) in the NAM group compared to the placebo group [44]. In patients with 
hemodialysis, t he documented safety profile of NAM include d primarily flushing, prurit us, 
hypotension, hepatotoxicity, and gastrointestinal upset.  Most studies reported NAM  associated 
transient thrombocytopenia without any bleeding events  in hemodialysis patients which  returned 
to normal range within weeks of discontinuation of intervention [43, 45, 46] . In contrast, studies 
conducted in peritoneal dialysis patients did not report such hematol ogic changes associated with 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
14 NAM [47]. It should be noted that NR does not induce prostaglandin -mediated flushing or 
vasodilatory responses [48]. One study tested NAM 100 mg twice daily for 6 months in pediatric 
population (a ge 7-17 yrs) with hyperphosphatemia undergoing maintenance hemodialysis [49]. 
NAM group reported diarrhea, nausea, vomiting , and flushing which were not significantly 
different from the control group and did not result in withdrawal from the study. Despi[INVESTIGATOR_040] a 
significant decline in mean platelet count from the baseline in the NAM group, the platelet level 
remained within the nor mal range and none of the participants experienced any bleeding 
disorder.      
 
N-methyl -2-pyridone -5-carboxamide or 2PY, a major metabolite of  NAM, is considered a 
uremic toxic in patients with impaired renal function [50, 51] . While serum 2PY level may 
increase significantly  with NAM supplementation [46], the intracellular concentration may not 
rise compared to baseline in hemodialysis patients [52]. In general, available data conclude that 
NAM is safe and tolerable in adults at doses of below 3 g/day [53]. Taken together t he available 
safety data of niacin and NAM indicate that in  patients with impaired re nal function both agents 
are tolerable  [54-56]. The prominent side effects of NAM at therapeutic doses (i.e., 1000 
mg/day) are gastrointestinal symptoms (mainly diarrhea) that generally resolve on treatment 
withdrawal or discontinuation . Develeopement of hetatoxicity require massive dose of NAM – 9 
g/day and prolong therapy for months may cause thromobocytopenia  [55, 56] . 
Based on the available data, the known potential risks of NR can be divided into those that are 
likely and those that are rare.  
 
Likely   
These risks are expected to occur in 5 -15 participants or less out of 100 participants.  
• Gastrointestinal disorders : nausea, heart burn (e.g., indigestion, gas, upper abdominal 
discomfort, and bloating ), diarrhea, transient changes in stool ; 
• Musculoskeletal disorders: b ack soreness , muscle soreness ; 
• Skin disorders: p ruritus , flushing, hives ; 
• Other disorders: l eg cramps , increased bru ising, excessive sweating;  
• Laboratory findings: liver function abnormalities; decrease in blood urea nitrogen ;  
 
Rare   
The following risk may occur at an unknown rate:   
• Hematologic profile – e.g., <10% reduction in hemoglobin  and platelet counts  
• Allergic reaction or hypersensitivity  
 
There is no available data on potential interactions between NR and standard treatment for 
comorbidities (concurrent medications) or any investigational agents for the treatment of 
COVID -19. Adminis tering NR concurrently with other agents may lead to antagonism or 
synergy or may have no effect.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
15 2.3.2  KNOWN POTENTIAL BENEFITS  
 
The benefits of nicotinamide riboside (NR) administration in COVID -19 participants to prevent 
or treat acute kidney injury are not currently known.  
 
2.3.3  ASSESSMENT OF POTENTIAL RISKS AND BENEFITS  
 
This trial protocol incorporates numerous design elements to minimize risk to participants to 
meet human participant protection requirement.  The dose of NR in this trial is comparable to the 
dose used in other published and ongoing clinical trials to increase blood NAD+ levels and have 
shown minimal to mild side effects.  The duration of treatment in this trial of [ADDRESS_506330] of these reported risks are mild in a 
grading scale  (see section 2.3.1 ). Based on prior data in healthy populations, obese participants  
and in those with AKI, there ha ve been no reported major adverse events. Minor adverse events 
include gastrointestinal  side effects, muscle and back pains. It remains possible that NR in 
patients with COVID -[ADDRESS_506331] NAD+ levels for kidney 
protection along with the relative lack of therapeutic options for AKI incidence and severity  it 
appears to reasonably balance potential risks with possible benefit that may outweigh such risks. 
By [CONTACT_401609], laboratory monitoring, soliciting of symptoms and 
incident reporting by [CONTACT_401610], the risk to participants will be minimized.  
 
Participants will receive the usual standard of care during hospi[INVESTIGATOR_401534] [ADDRESS_506332] of care includes a daily review of health status, 
participant’s report of any new sy mptoms and complaints, targeted physical exam and routine 
laboratory tests. Adverse events data will be retrieved from the electronic health records ( EHR ) 
and entered into the case report form for evaluation and comparison using the baseline values. 
For an y missing data in the EHR and to collect additional information, the study team will obtain 
data from the primary care team and the participant. If participants are discharged from the 
hospi[INVESTIGATOR_401535], they will be contact[CONTACT_401611] o visit or phone daily 
during period of intervention (first 10 days after enrollment) by a member of the study team to 
assess for any new symptoms or any intercurrent medical events and changes in symptoms 
severity from the previous day. After the [ADDRESS_506333] a 
study visit  at Day 30 and Day 90 and will be asked about intercurrent events.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
16 All collected AEs will be initially reviewed and evaluated by [CONTACT_55794]. All AEs will 
be electronically captured into the study database. The site investigators will also make initial 
assessment of severity and causality. Unexpected AEs and SAEs will be submitted to an 
independent Safety Adjudication Committee (SAC) for further evaluation. The SAC will be 
composed by a team of medical monitors, one from each study site and independent of the study 
investigators, who will review unexpected AE /SAE data on a weekly basis during the active 
phase of the study. The SAC chair will meet weekly during the course of t he study and be 
chaired by [CONTACT_401612]. If a SAC member identifies a pattern of 
unexpected AEs or SAEs that is out of proportion to the current understanding of the natural 
history of the disease, the DSMB will be asked to review unb linded safety data in an ad hoc 
meeting. The DSMB will be appointed by [CONTACT_49010] .  
Federal regulations at 45 CFR 46.111 (a)(2) require that “the risks to subjects are reasonable in 
relation to anticipated benefits, if any, to subjects, and the importance o f the knowledge that may 
reasonably be expected to result.” Based on the preceding assessment of risks and potential 
benefits, the risks to participants are reasonable in relation to anticipated benefits.  
3 OBJECTIVES AND ENDPOINTS  
 
Table 2: Study objectives , endpoints, and justification for endpoints  
 
OBJECTIVES   ENDPOINTS  JUSTIFICATION FOR 
ENDPOINTS  
Primary  
• To determine the effect of 
nicotinamide riboside (NR) on 
whole blood NAD+ levels in 
hospi[INVESTIGATOR_401536] -19 infection and AKI 
during the 10 -day intervention 
period ; 
• To evaluate the safety of NR 
in patients with COVID -19 
infection and AKI during the 
10-day intervention period . • The primary endpoint is the 
rate of change in whole 
blood NAD+ level over the 
10 day period from 
baseline  to day 10.  
• Safety of NR in 
hospi[INVESTIGATOR_401536] -19 and AKI 
(defined as the occurrence 
of at least one serious 
adverse event of grade 3 or 
higher or the occurrence of 
thrombocytopenia defned 
as >25% decline in blood 
platelet count from 
baseline.   • Recent c linical data indicate 
a reduction of blood NAD+ 
level in AKI patients and an 
increase in NAD+ in 48 hrs 
with NR treatment;   
• The safety of NR in 
COVID -19 patients is not 
known  
Secondary  
• To determine the effect of 
NR on changes in AUC • The rate of change in  AUC 
serum  creatinine 
benchmarked to baseline;  • The recovery of AKI, as 
assessed by [CONTACT_401613] -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
17 serum creatinine from 
baseline during the 10 -day 
intervention ;  
• To determine the effect of 
NR on serum AUC, dialysis, 
and death with an ordinal 
categorical outcome with 
four categories (labeled 1, 2, 
3, 4), defined as, in  order 
from least to most severe 
disease, 1. Serum creatinine 
AUC < median, 2. Serum 
creatinine AUC ≥ median, 3. 
Dialysis, 4. Death;  
• To evaluate the effect of NR 
on on MAKE (composite 
criteria defined as 
development or progression 
of chronic kidney disease ), 
the initiation of long -term 
dialysis, or death from any 
cause) at 30d and 90d post 
randomization . 
• To determine the effect of 
NR on kidney function  
defined by [CONTACT_401614] 30d and 90d 
post randomization . • An ordinal categorical 
outcome with four 
categories (labeled 1, 2, 3, 
4), defined as, in order 
from least to most severe 
disease, 1. Serum 
creatinine AUC in the first 
tertile, 2. Serum creatinine 
AUC in the second terti le, 
3. Serum creatinine AUC 
in the third tertile, 4. Death;  
• Time to first occurrence of 
MAKE defined as 
doubling of serum 
creatinine, the initiation of 
long-term dialysis, or 
death from any cause at [ADDRESS_506334] 
randomization ; 
• Kidney function def ined 
by [CONTACT_131328] (eGFR) and 
proteinuria at 30d and 90d 
post randomization . creatinine during the 10 
days of intervention and 
benchmarked to baseline, 
has been linked to reduced 
progr ession of chronic 
kidney disease (CKD).  
• The ordinal categories 
address the hierarchy of 
increase in severity as has 
been used in recent 
COVID -19 studies  as per 
the World Health 
Organization clinical 
progression scale  [57, 58]   
• AKI may progress to CKD 
which is associated with 
need for dialysis and 
increased mortality.  
 
 
Exploratory  
• To determine the 
relationship of whole 
blood NAD+ levels with 
AUC creatinine and 
surrogate markers of AKI 
such as kidney injury 
molecule -1 (KIM -1) and 
neutrophil gelatinase -
associated lipocalin 
(NGAL);  • Correlations between   
whole blood NAD+, AUC 
serum creati nine, and 
surrogate markers of AKI 
such KIM1 and NGAL ; 
 • AUC of serum creatinine is 
a direct assessment of the 
duration and severity of 
AKI; KIM -1 and NGAL are 
promising surrogate urinary 
biomarkers of AKI 
however, their clinical 
utility in COVID -19 patients 
with AKI is not known ; 
 
 
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
18 4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
 
The overall study design is depi[INVESTIGATOR_6517] 1.  
 
                                                                                           No AKI  within 10 days       
 
 
                                                                    
                                                                   Meets KDIGO AKI stage    
 
                                                                                     
 
 10 days from adm to meet AKI Stage  I-III                         Intervention Period 1 -10 days  D30    D90       
                                                                                                   In-hospi[INVESTIGATOR_401537] (study days)     
  
                                                                                                                       In-hospi[INVESTIGATOR_401537] & early D/C <SD10  
                                                                                                                                    Daily home fingerstick blood Cr until D10  
                                                                                                                                    Serum Cr on D10  
  Figure 1. Study flow – screening and enrollment  
 
 
• Phase 2 Study  
• This is a prospective, pi[INVESTIGATOR_2268], double -blind, placebo -controlled, multicenter, clinical 
interventional trial  
• Intervention: 2 arms  – study drug ( Nicotinamide riboside , NR ) and placebo  for 1 0 days  
• Two follow up visits: at day 30 and day 90  
 
4.2 SCIENTIFIC R ATIONALE FOR STUDY DESIGN  
 
The NIRVANA Protocol describes a trial design to provide pi[INVESTIGATOR_401538] (NR) for the treatment of incident AKI or AKI severity in patients with 
COVID -[ADDRESS_506335] of care.  
 
AKI in patients with SARS -CoV -2 is being increasingly recognized as a major risk factor of 
morbidity and mortality. The incidence of patients with AKI ranged between 22% to 46% in 
independent analyses of inpatients with SAR S-CoV -2 in NYC [24]. Recently, data from the 
Northwell Health System, NYC reported that 90%  of COVID -19 patients on mechanical 
ventilation develope d AKI [23]. The Mount Sinai Health System [24], also from NYC, 
documented a 3 t imes higher incidence of Stage 3 AKI vs Stages 1 or 2. In addition to these 
COVID -19 hospi[INVESTIGATOR_401539] 
(Scr)  Screening  
Randomize  
NR 
Placebo  
Follow -
up Period  
Expected 
scenario  
Participants with  
early discharge <10 
study days  Exclude  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506336] ratio of 4.7 in Stage 3 AKI patients [59]. Similar findings were found by [CONTACT_401615] a 52% mortality rate in patients with AKI, compared to mortality of only 9% in those 
without AKI admitted to the ICU. Surprisingly, 44% of SARS - COVID -19 patients with  AKI did 
not fully recover kidney function by [CONTACT_401616][INVESTIGATOR_307] [24]. Recent data 
suggest that mortality is lower in hospi[INVESTIGATOR_41374] -19 [25]. Therefore, strategies 
to identify and treat patients with impending AKI will be of major value to reduce mortality, 
hospi[INVESTIGATOR_7577], hospi[INVESTIGATOR_401540].  
 
To date, no standard treatment is available for SARS -CoV -2 infection. Since “cytokine storm” is 
considered a primary contributing factor to AKI and disease severit y in patients with COVID -19 
[28, 29] , convective -based clearance may be a useful modality for removal of large -sized 
cytokines [60, 61] . However, this invasive approach may not be feasible as initial treatment for 
all COVID -19 patients at the time of hospi[INVESTIGATOR_063]. Patients  with severe COVID -19 
infection often present with high levels of cytokines in the plasma, such as IL -6 [62, 63] . Clinical 
trials using anti -IL6 receptor (Sarilumab and Tocilizumab) are underway in hospi[INVESTIGATOR_249117] -19 [64]. Human recombinant soluble ACE2 (hrsACE2) has been touted as a 
competitive interceptor of SARS -CoV -[ADDRESS_506337] 
tissues [65]. Although tolerable, the efficacy of hrsACE2  to prevent AKI is unknown [66, 67] .  
Treatment to inhibit viral replication with Remdesivir may reduce hospi[INVESTIGATOR_401541] -19 pa tients compared to placebo [68]. 
Another approach is to focus on the cellular target of the virus. Cyclosporine, an 
immunosuppressor, has the potential to suppress the CD147 -cyclophilin axi s targeting ACE2. 
However, due to the potential high -risk of cyclosporine to cause AKI, it’s use in AKI would be 
difficult to manage [69].  
 
It is likely that the overall burden of AKI in COVID -[ADDRESS_506338] true pre -admission baseline kidney 
function and pre -admission serum creatinine values might not be readily available. A key 
challenge for breakthr ough treatments will be to establish paradigms for implementing precision 
medicine to prevent and mitigate progression of AKI in newly admitted patients with COVID -
19. There are no known treatments for AKI including AKI due to COVID -19. The current 
proposa l will address several major unmet needs by [CONTACT_58833] a novel therapeutic approach for 
AKI with NR  in patients admitted with COVID -19. 
 
4.3 JUSTIFICATION FOR DO SE 
 
NR (500 mg orally twice a day) or placebo will be administered for a period of 10 days. NR or 
matching placebo will be given via nasogastric tube in those participants who are intubated or 
felt to be at aspi[INVESTIGATOR_50498]. [70] NR is more orally bioavailable than nicotinamide or niacin [38]. 
Limited data are available to shed light on the PK of NR in patients with comorbidi ties such as 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
20 obesity, diabetes, CKD and hypertension. One study [38] with healthy volunteers that 
administered NR in escalating dose regimen for 9 days reported that following the Day 9 dose, 
blood NR concentration peaked (Cmax) at t = 3 hours. The study did not evaluate PK after initial 
dose [38]. The NR dosing interval in the proposed study derives from the average st eady -state 
blood concentration based on the area under the blood concentration -time curve over the 12 -hour 
dosing interval [38]. In a [ADDRESS_506339] level 
(LOAEL) for NR was 1000 mg/kg/day [8].  
 
Nicotinamide riboside is a dietary supplement, which is commercially available and designated 
as a “Generally Recognized as Safe” by [CONTACT_2165] ( FDA ) at oral doses 
of up to 1000mg (four 250 mg capsules) daily for adults  [17]. The dietary supplement NR has 
been demonstrated to be well -tolerated with mild, if any side effects reported. There are several 
clinical trials currently underway employing variable dosages, including 1000 mg/day proposed 
in the current protocol, for nume rous different conditions, both biomedical and behavioral [71]. 
The dose of 500 mg bid for 10 days was chosen as 1000 mg/d was found to give peak NAD+ 
levels in blood at 7 and14 days after starting oral administration of NR [8] with no further 
increase up to 56 days of treatment. The frequency of adverse effects in symptoms, vital signs or 
routine lab tests (ch emistries and complete blood counts) in the 1000 mg/d of NR (group) was 
not different from the placebo group. Plasma and urine levels of the NAD+ metabolites were  
found to increase significantly in participants given the dose of 1000 mg/d of NR [8]. 
 
4.[ADDRESS_506340] meet all of the following 
inclusion criteria:  
1. Provision of signed and dated informed consent form from a participant or legally 
authorized representative (LAR);  
2. Male or female, >18 years old;  
3. Admitted to hospi[INVESTIGATOR_4791] a laboratory diagnosis of COVID -19 infection and COVID -19 
related illness and evidence of persistent AKI as defined by [CONTACT_67490]: 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
21 Improving Global Outcomes (KDIGO) guidelines during the first 10 days following 
admission (Table 3);  
4. Willing to adhere to the study intervention regimen;  
 
Rationale: Persistent AKI Stage [ADDRESS_506341] of care  management by [CONTACT_401617]. The 
NIRVANA study team will monitor serum creatinine daily and participants with sustained AKI 
will proceed to randomization.  
 
5.2 EXCLUSION CRITERIA  
 
An individual who meets any of the following criteria will be excluded from participation in this 
study:  
1. Hypersensitivity to nicotinamide riboside (NR);  
2. Pregnant or lactating women confirmed with positive laboratory pregnancy tests as 
per local requirements;  
3. eGFR <15 mL/min/1.73 m2 as per the Chronic Kidney Disease Epi[INVESTIGATOR_401542];  
4. Maintenance renal replacement therapy or initiation of renal replacement therapy 
before randomization  
5. Currently on NR or nicotinamide or vitamin B3 (niacin) supplementation 
(multivitamins are allowed);  
6. Concomitant cirrhosis of liver or acute liver failure;  
7. Any medical history or condition that might, in the opi[INVESTIGATOR_401543], put the participant at significant risk if he/she were to participate in the 
trial; 
8. Individuals with kidney transplant ; 
9. Individuals with blood platelet count < 100,000/microL;  
 
Rationale: The exclusion criteria are primarily desi gned for patient safety. In addition, these 
exclusion criteria address some uncertainties in the COVID -19 severity and effects of 
concomitant medications on disease progression . For example, the incidence of AKI in kidney 
transplant recipi[INVESTIGATOR_401544] -19 is not well studied [73]. Moreover, kidney transplant 
recipi[INVESTIGATOR_401545] 3: Staging of AKI by [CONTACT_67490]: Improving Global Outcomes [72]  
AKI Sta ge Serum Creatinine  Urine output  
1 1.5 – 1.9 x baseline  <0.5 mL/kg/h for 6 -12 h 
2 2.0 – 2.9 x baseline  <0.5 mL/kg/h for ≥12 h  
3 3.0 times baseline  OR i ncrease in serum 
creatinine  ≥4.0 x baseline OR initiation of 
renal replacement therapy  <0.3 mL/kg/h for ≥24 h OR 
anuria for ≥12 h  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
22 outcomes . An optimal management of immunosuppressive agents in this patient group with 
COVID -19 is not clear [74]. 
 
5.3 LIFESTYLE CONSIDERATIONS  
 
Not-applicable.  
 
5.4 SCREEN FAILURES  
 
Pre-Screening  
The site investigator or delegate will pre -screen hospi[INVESTIGATOR_191568] -19 (a positive laboratory test for SARS -CoV -2) for eligibility.  After a COVID -19 
patient is admitted to the hospi[INVESTIGATOR_4791] a positive laboratory diagnosis of COVID -19, the study 
team will be notified by [CONTACT_401618] . In addition, the study team  will identify 
eligible participants from the hospi[INVESTIGATOR_53756] -19 database which is periodically updated every 6 
to 8 hours.   
 
Screening – Assessment of Eligibility and Exclusion Tracking  
Eligibility screening will be performed by [CONTACT_3476], under IRB -approved HIPAA waiver, 
using the EHR.  Certain screening  visit laboratory assessments will be performed to determine 
eligibility after obtaining consent  – blood draw for serum creatinine (if no routine value available 
within 24 hours prior to consenting) and pregnancy test for women with childbearing potential.     
 
For participants  who appear to meet inclusion criteria during screening, an electronic case report 
form will be completed to determine eligibility and track exclusions. All potential participants 
for which EHR screening is performed will be entered in  a de-identified manner on the site 
screening log. At the time of entry into the screening database the participants will be assigned a 
screening number. The screening log will be maintained in the study REDCap database and will 
capture inclusion and exclusion criteria leading to a determination of  “eligible” or  “ineligible”. 
Additionally, the screening log will cover the period between screening and enrollment. As such, 
the screening log will also document the reason (s) “eligible” potential participan ts were not 
enrolled. The screening log will not contain identifiable health information .  
 
The complete eligibility determination process may be suspended prior to complete screening 
procedures at any time if an exclusion criterion is identified by [CONTACT_158983]. Only the reason 
for ineligibility will be collected on screen failures. For women with child -bearing potential, 
screening failure will be determined by [CONTACT_401619]. 
Participants who are found to be ineligible will be told the reason for ineligibility and  de-
identified variables will be retained including month and year when participant  was evaluated for 
study, age, sex, ethnicity, and reason(s) why the participant  was excluded . Participants who fail 
screening w ill receive standard management for COVID -19 and comorbidities. Participants are 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
23 eligible to enter this study only once during the accrual duration. Screen failed participants will 
not be allowed to re -screen.   
 
A participant already enrolled  in an observational study  or an open -label randomized clinical 
trial (RCT)  would  be eligible to participate in the NIRVANA study , provided eligibility criteria 
are met.  With respect to double -blind RCT , the steering committee will determine trial by [CONTACT_401620] 
a participant is eligible to enroll in the NIRVANA study.  
 
If a participant  appears to meet all eligibility criteria, the site investigator or delegate will 
approach the treating clinician to ask permission to approach the participant  or LAR to confirm 
eligibility, discuss potential study recruitment, and proceed with informed co nsent.  
 
Process of Obtaining Informed Consent (also see section [IP_ADDRESS] ) 
Informed consent will be obtained from the participant or LARy. In most instances, bringing a 
paper consent form and pen to the bedside of a participant  with known COVID -19 and then 
taking these out of the room would violate infection control principles and policies. Given the 
infectious risk from COVID -19 and potential shortages of personal protective equipment (PPE), 
there is a moral and practical imperative to minimize face -to-face contact [CONTACT_401621] -clinical personnel. The current pandemic  also presents unique challenges to obtaining 
consent from participant’s LAR. To minimize infectious risk, many institutions are not allowing 
visitors to enter the hospi[INVESTIGATOR_307]. Furt hermore, the LAR is likely to have been exposed to the 
participant  and may therefore be under self -quarantine at the time of the informed consent 
discussion. Therefore, in addition to the traditional approach of an in -person consent discussion 
and signed paper informed consent, we will allow use of “no -touch” consent pro cedures.  
 
5.5 STRATEGIES FOR RECRUITMENT AND RETENTION  
 
Participants will be recruited from three participating sites: the University of [LOCATION_007] Health San 
Antonio (UTHSA), Icahn School of Medicine at Mount Sinai, [LOCATION_001], NY, and University of 
Washington (UW), Seattle , WA . The single IRB (sIRB) at the Washingto n University in St. 
Louis (FWA00002284) will serve as the Central IRB for all three participating sites. We will 
recruit and consent eligible participants and will advance them into the Treatment Period. A total 
of 100 participants will be randomized.  
 
Each participating site and the coordinating site (UTHSA) will contribute to recruitment of study 
participants. Recruitment methods will focus primarily on the selection of eligible participants 
via identifying patients admitted to the respective hospi[INVESTIGATOR_401546] a diagnosis of COVID -19. Lead 
investigators at each site are physician scientists who will have direct access to eligible 
participants. For efficient recruitment, each site will employ the following approaches. After a 
COVID -19 patient is admitted to th e hospi[INVESTIGATOR_4791] a new positive laboratory diagnosis of 
COVID -19, the study team members will be notified by [CONTACT_25963] -19 Admitting Team. All 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506342] access to the respective hospi[INVESTIGATOR_53756] -19 admission logs and EHR enabling 
them to review several eligibility criteria. The study investigators or clinical coordinators will 
approach the potentially eligible participants or LAR (when appropriate) and inform them of the 
study protocol.  All participants will provide written consent for participation in the study. Sites 
have the ability to use one of the FDA approved options for o btaining written signature [INVESTIGATOR_74964] a 
pandemic, based on their institutional requirements . 
  
During consenting process, each participant will receive clear and detailed information about the 
NIRVANA study with an emphasis on risks, benefits, and alternative to enrollment. Participants 
will be given opportunities and time to learn about ongoing cli nical trials for COVID -[ADDRESS_506343] 80% adherence with study intervention  is 
expected because of short (10-day) intervention  with minimal burden for study participants. NR 
is a safe nutritional supplement and poses only a few side effects which are mild in nature.  It is 
likely, howe ver, that 15% of enrolled  participants may withdraw from the current study and 
enroll to another COVID -[ADDRESS_506344] an additional attrition rate of 5% during the follow -
up period  due to  extended isolation, travel restrictions, or relocation. Statist ical methods will be 
based on the Intent -to-Treat Principle that every randomized subject will be assumed treated as 
randomized and all randomized patients will be included in the analysis regardless of 
noncompliance , protocol violations  or withdrawals.  
 
The data coordinating center (DCC) at UTHSA will email weekly recruitment reports showing 
study -wide weekly and cumulative enrollment in baseline and randomization. The reports will 
also include each site’s current baseline goal, achievem ent of baseline goal, randomization goal, 
and achievement of randomization goal. Clinical site investigators will meet weekly with their 
study teams to discuss progress on weekly goals, identify barriers and problems, and revise 
recruitment plans as necess ary. The investigators at three participating sites will meet by 
[CONTACT_401622]’s recruitment progress, share 
problems and successes, and revise recruitment plans as necessary.  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
25 The enrollment will be tra cked and paused after 50 participants until the DSMB reviews primary 
outcome data from all 50 participants; a decision to continue enrollment will be made by [CONTACT_401623] . 
 
Participan t retention is paramount to the success of this study. The following approaches will be 
included to minimize loss of data and to maximize the retention especially for the follow -up 
visits: participants will be reminded about the upcoming visits at least a week before; asking a 
participant for the name [CONTACT_3669] [CONTACT_401624] a family member or friend who can be contact[CONTACT_401625]; and use of email contact (with care to maintain confidential medical 
information over nonsecure email). As COVID -[ADDRESS_506345] -COVID care program to enhance 
retention of our participants for the duration of this study. For any missing visit/contact [CONTACT_401626], the reason for the missing visi t/contact [INVESTIGATOR_1238]/or data will be recorded in the REDCap 
case report form (eCRF).  
 
Replacement of Participants:  
Randomized participants who are randomized but do not receive study intervention (NR or 
placebo) may be replaced to maintain the stipulated cohort sizes. This would include participants 
who are randomized and then withdrew consent before receipt of the int ervention. Participants 
who are discontinued from further dosing or follow -up procedures or withdraw their informed 
consent to all follow -up study procedures may be replaced, if deemed necessary by [CONTACT_163399], to ensure that data are collected from a sufficient number of participants. The SAC 
will be notified within [ADDRESS_506346] will be made jointly b etween the site investigator and SAC.  
 
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
   
6.1.1  STUDY INTERVENTION  DESCRIPTION  
 
Baseline Visit (Day 1)  
After obtaining consent, baseline visit procedures will be performed  as listed in Table 1 
(Schedules of Activities  in Section 1.3) . Participants will be randomized  after abstracting the 
following data from the EHR : sociodemographic, contact [CONTACT_3031], medical/surgical history, 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506347] results .  
 
Randomization will be accomplished through the use of an online randomization service. 
Participants will be randomly allocated to 1:1 ratio to receive either nicotinamide r iboside (NR) 
or placebo. Only the study statistician s (Drs Micha lek and Zelnick) and the local hospi[INVESTIGATOR_401547], respectively . Study investigators and study 
participants will be blinded to the intervention assignments. Neither the statistician s nor the 
pharmacist will have direct contact [CONTACT_401627].  
 
Eligible study participants enter intervention phase after consenting to the study protocol:  
• Nicotinamide riboside (NR, Niagen🄬) or placebo will be administered orally (or via 
nasogastric tube) 500 mg twice a day for 10 days during hospi[INVESTIGATOR_401548] 10 d ays from the hospi[INVESTIGATOR_307] . 
• Placebo capsule manufactured by [CONTACT_401628]🄬 
 
TREATMENT PERIOD  
All measures related to study treatment visits are harmonized to standard of care to minimize 
care interruption and disruption to hospi[INVESTIGATOR_401549]. Most of the  treatment procedures are 
standard of care or routine procedures for COVID -19 participants in an acute care setting. These 
data will be obtained from the EHR. If any treatment procedure is not available through the 
EHR, the study team will obtain these data from the primary care team or directly from the 
participant. Where multiple results are present in the EHR, they will all be recorded in the study 
database so that all relevant values are captured. A summary of th e trial’s schedule of event is 
included in Table 1  (Section 1.3) . 
 
Treatment Visits 1 to 10 (Day 1 to Day 10) for participants with hospi[INVESTIGATOR_401550] 10 days  
Participants will be assessed daily while hospi[INVESTIGATOR_401551]. The 
following clinical and laboratory data will be collected daily from the EHR during the Visits 1 to 
10 while hospi[INVESTIGATOR_057]:  
1. Review of current medications  and treatment  
2. Adverse events  
3. Vital Signs, including temperature, pulse rate, respi[INVESTIGATOR_697], and systolic and diastolic 
blood pressure   
4. Study drug administration and accountability  
5. Evaluation of APACHE -II (Acute physiology and chronic health evaluatio n II) 
6. Assessment of fluid intake, if applicable  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
27 7. Assessment of urine output, if applicable  
8. Respi[INVESTIGATOR_108951]  
9. Ascertainment of endpoint assessment (serum creatinine and urine volume), mortality, 
intensive care unit (ICU) transfer rate, and length of ho spi[INVESTIGATOR_4408]  
10. First morning void urine collection (optional and if  indicated by [CONTACT_401629])  
11. Blood collection  
 
The list of daily laboratory test s is provided in Table 4.  
 
Treatment Visits 1 to 10 (Day 1 to Day 10) for participants with hospi[INVESTIGATOR_401552] <10 
days  
During each daily virtual phone visit, following information will be collected from each 
participant and/or family caregivers:  
1. Review of current medications  and treatment  
2. Any new health issues or changes from previous day  
3. Vital Signs, including temperature, pulse rate, respi[INVESTIGATOR_697], and systolic and diastolic 
blood pressure  (if available)  
4. Respi[INVESTIGATOR_108951] (if available)  
5. Study drug administration and accountability (virtual rev iew of compliance log)  
6. Endpoint assessment ( fingerstick  creatinine using StatSensor  Xpress®) 
7. Ascertainment of mortality or hospi[INVESTIGATOR_401553] 9 by [CONTACT_401630] r service (FedEx same day delivery service) for delivery to the hospi[INVESTIGATOR_54998]. Urine specimens will be aliquoted and stored at the hospi[INVESTIGATOR_401554].   
 
To monitor clinical measures necessary for primary outcome , a phlebotomist and a study team 
member will  visit participant’s home for the d ay [ADDRESS_506348] the POC device and 
urine specimen from the participant.  Both blood and urine specimens will be delivered to the 
hospi[INVESTIGATOR_401555] . The biosamples will be  aliquoted and stored at the hospi[INVESTIGATOR_401556]. The research aliquots will then be pi[INVESTIGATOR_401557].   
 
FOLLOW -UP PE RIOD:  
There are t wo follow -up vis its.  
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
28 Follow -up Visit s 11 and 12 (Day 30 ± 3  and Day 90 ±3 ) 
The Day 30 ± 3 and Day 90 ± [ADDRESS_506349] blood and urine if participant cannot or is unwilling to come to the clinic. For 
participants who are allowed and wil ling to come to clinic, the following assessments will be 
performed at the clinic : 
1. Review of current medications  and treatment  
2. Vital Signs, including temperature, pulse rate, respi[INVESTIGATOR_697], and systolic and diastolic 
blood pressure  
3. Physical examination  
4. Endpoint assessment  
5. Adverse events – collection of health status based on participants reported and review of 
EHR  
6. Ascertainment of mortality or hospi[INVESTIGATOR_059]  
7. First morning void or random urine collection  
8. Blood collection  
6.1.2  DOSING AND ADMINISTRATION  
 
Participants, randomized to the study drug nicotinamide riboside (NR) group, will receive a total 
daily dose of 1000 mg (four 250 mg capsules) NR administered orally  or via nasogastric  tube as 
500 mg (2 capsules) every 12 hours for up to 10  days during hospi[INVESTIGATOR_059].  
 
Participants, randomized to the placebo group, will receive matching placebo, two capsules 
orally every 12 hours for up to 10 days during hospi[INVESTIGATOR_059].  
 
Participants with hospi[INVESTIGATOR_271477] <[ADDRESS_506350] timing 
of administrations.  
 
6.2 PREPARATIO N/H ANDLING/ STORAGE/ ACCOUNTABILITY  
   
6.2.1  ACQUISITION  AND ACCOUNTABILITY  
 
NR and matching placebo will be obtained from ChromaDex, Irvine, CA. NR is manufactured in 
a Good Manufacturing Practice (GMP) -compliant facility according to ISO/IEC [ZIP_CODE]:2005 
standards.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
29  
For all study drugs (NR and placebo), a system of numbering in accordance with all 
requirements of Good Clinical Practice (GCP) will be used, ensuring that each dose of study 
drug can be traced back to the respective batch of the ingredients. L ists linking all numbering 
levels will be maintained by [CONTACT_978]. A complete record of batch numbers and expi[INVESTIGATOR_401558].  
 
Following randomization of a participant, a computer -generated system will generate 
randomization number, medication numbers, and treatment code. During the hospi[INVESTIGATOR_401559] a participant as prescribed: [ADDRESS_506351] will prepare study drug for nasogastric tube administration as per guidelines 
from ChromaDex .  
 
Participants with hospi[INVESTIGATOR_271477] <10 days will be provided with study drug in a pi[INVESTIGATOR_401560]. These participants will 
receive clear verbal and written instructions on administering of and compliance with study drug.   
 
All expi[INVESTIGATOR_401561] t o supplier ChromaDex for destruction.  
6.2.2  FORMULATION, APPEARANCE, PACKAGING, AND LABELING  
 
NR is supplied as capsule white in color and each capsule contains active ingredient 
nicotinamide riboside chloride 250 mg. Placebo capsules will be identical in appear ance (size, 
shape, color).  The study drug will be labeled as required by [CONTACT_2371]: Caution: New Drug. Limited 
by [CONTACT_12201].  
 
Preparation of NR or matching placebo for administration via nasogastric tubing will be prepared 
daily, as nee ded, in an aqueous suspension in [ADDRESS_506352] STORAGE AND STABILITY  
 
All study drugs will be stored at the respective site hospi[INVESTIGATOR_401562]. Study drugs will be inaccessible to unauthorized personnel. Both 
NR and placebo are stable at room temperature. Storage conditions (m inimum and maximum 
temperatures) and a complete record of batch numbers and expi[INVESTIGATOR_401563].  
 
Participants discharged before completing [ADDRESS_506353] at  temperature below 25⸰C preferably in a refrigerator.  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506354] will 
dissolve brown sugar in water. For  example, to match 1 gram of Niagen in 50 mLs of purified 
water, placebo will be prepared by [CONTACT_116125] ~75 mgs of brown sugar in 50 mLs of purified 
water for administration via NG tube.   
 
6.3 MEASURES TO MINIMIZE BIAS : RANDOMIZATION  AND BLINDING  
 
Eligible participants who provide voluntary consent will advance to randomization. In order to 
minimize bias, the set inclusion and exclusion criteria offer broader participation from a wider 
range of participants who may be eligible in three geographically diverse s tudy centers. The set 
of inclusion and exclusion criteria  do not compromise the scientific integrity.   
 
The study drug (NR or placebo) packaging and labeling will be designed to maintain the blinding 
of the investigator’s team and the participants. The st udy drug allocation will remain blinded to 
the study participants and study investigators according to standard operating procedures. The 
randomization and blinding procedure s will be described in a corresponding  manual of operation 
(MOP) .  
 
If participant s require nasogastric tube administration, NR will be available in a powder form 
and the NR and placebo will be prepared by [CONTACT_401631]. Using a dark opaque sterile drapi[INVESTIGATOR_401564]. The h ospi[INVESTIGATOR_401565].  
  
Under normal circumstances, the blind should not be broken until all participants have completed 
the study and the database is finalized. However, the treatment blind may be broken to provide 
unblinded information to the study site only if specific emergen cy treatment/course of action 
would be dictated by [CONTACT_363125]. In the event of an 
emergency or any finding that requires unblinding, the investigator may break the blind for an 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
31 individual participant. This will allow th e investigator, or other responsible person, to identify 
the study drug if there is an emergency, without jeopardizing the double -blind integrity of the 
remainder of the study. The code can be broken by [CONTACT_093], or other responsible person, 
when k nowledge of the participant’s treatment is required for the clinical management of the 
participant. If it becomes necessary to know the individual treatment during the study and thus to 
break the code for that participant, the date and reason for unblindin g are to be recorded on the 
relevant source document  and in the REDCap eCRF . 
 
6.[ADDRESS_506355] according to l ocal procedures . A 
compliance log will be maintained in the eCRF containing participant ID, bottle number and 
batch number, route, and date and time of administration. Problems with participant medication 
adherence during hospi[INVESTIGATOR_401566]. Upon discharge, if this occurs before 10 days of hospi[INVESTIGATOR_059], 
participants will receive study drug for the remaining days to complete a total duration of 10 
days. These participants will re ceive verbal and written instructions on administering study drug. 
Participants will be asked to keep a written log as to when they self -administered study drug with 
dates and times recorded. If a care provider (i.e., family member) is present in the parti cipant’s 
home, daily pi[INVESTIGATOR_401567]. 
 
6.5 CONCOMITANT THERAPY  
 
All standardized treatment and management for any comorbidity and concomitant condition are 
permitted. Concomitant therapy with niacin, nicotinamide, NR and their derivatives are prohibited 
during the duration of the study.  
 
6.5.1  RESCUE MEDICINE  
   
To our know ledge there is no specific rescue medicine for NR as there is no known toxicity 
associated with this compound. If a rescue medicine is being considered for a participant for 
underlying COVID -19 or other intercurrent illness , this  may be a reason that warra nts stoppi[INVESTIGATOR_117120]. Any such decision will be made by [CONTACT_401632].  
 
7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT  
DISCONTINUATION /WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
32  
Discontinuation from study intervention does not mean discontinuation from the study  (i.e., 
withdrawal of consent) , and remaining study procedures will be completed as indicated by [CONTACT_60658].  Randomized partici pants  who wish to discontinue study medications will be 
encouraged by [CONTACT_7880] [INVESTIGATOR_401568], lab oratory  tests, and 
data collection so data will be available for intent to treat analysis of the trial. The site PI [INVESTIGATOR_401569] . 
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
Participants are free to withdraw from participation in the study at any time upon request, for any 
reason, and without any consequence. Participants should be listed as having withdrawn consent 
only when they no longer wish to participate in the study and no longer authorize the 
investigators to make efforts to continue to  obtain data.  A participant has a right to withdraw 
from the current study and enroll in a different research study at any time point. However, 
participants will remain in the current study and all data will be collected as per the Schedule of 
Activities  (section 1.3) , Table [ADDRESS_506356] the right to discontinue the study drug at any time, which may be 
due but not limited to the following reasons:   
• For an individual participant, a sus pected drug -related event of hypersensitivity Grade 2 or 
higher;  
• The investigator believes that for safety (e.g., SAE) or tolerability reasons it is essential for 
the participant to stop treatment;  
• The investigator formally unblinds the participant’s treat ment allocation for safety reasons;  
• The participant  requires renal replacement therapy or dialysis of any type (Note: The 
requirement for dialysis is the only endpoint for which treatment with double -blind study 
drug should be discontinued;  
• The participant  takes prohibited NR supplements (multivitamins are allowed);  
• Newly reported results of parallel clinical studies and/or animal studies indicating toxicity, 
teratogenicity, carcinogenicity or reproduction toxicity of NR at similar doses administered 
in thi s study;  
 
Participants who are permanently discontinued from receiving investigational product will be  
followed for protocol -specified assessments unless consent is withdrawn from further study 
participation, or the participant is lost to follow -up.  
 
In the event of a study drug discontinuation due to safety and tolerability, participants will 
continue to receive available and/or standard management for COVID -19 and comorbidities as 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
33 clinically indicated. Participants who discontinue study drug will continu e subsequent study visit 
procedures (including biosample collections) to assess safety and worsening or progression of 
any health issues that might be attributable or plausibly related to study drug. As the study is an 
intent to treat analysis, all partici pant data will be obtained and processed in the same manner 
regardless of study drug discontinuation for any reason.  
 
The reason for participant discontinuation or withdrawal from the study will be recorded on the  
REDCap  eCRF. Withdrawal of consent prior to receipt of study drug will constitute a screen -
failure and will be recorded. Participants who sign the informed consent form and are 
randomized but do not receive the study intervention may be replaced. Participants who sign the 
informed consent form, and are randomized and receive the study intervention, and subsequently 
withdraw, or are withdrawn or discontinued from the study, will not be replaced.  
 
Data recorded up to the point of withdrawal will be included in the trial a nalysis, unless consent 
to use data has also been withdrawn. Withdrawal of consent after randomization and 
administration of one or more doses of study drug will lead to discontinuation of study 
interventions but study site will request access to  EHR  for d ata related to the trial.  
 
Criteria for Stoppi[INVESTIGATOR_401570]  
(1) adverse events, (2) clinical deterioration, or (3) evidence of an alternative cause to the 
participant’s  symptoms. Study intervention will also be discontinued permanently when a 
participant:  
a) receives dialysis treatment for the management of AKI;  
b) develops thrombocytopenia defined as <75,000/ microL  in blood platelet count ; 
c) is found to have abnormal liver function test (AST, ALT, total bilirubin, or 
alkaline phosphatase) >4 times the upper limit of normal without other 
identifiable cause;  
d) is found to have abnormal serum CPK levels >4 times the upper limit of normal 
without other identifiable cause .    
 
If a participant experiences an AE that the patient (or LAR ), the treating clinicians, or 
investigators feel merits temporarily or permanently stoppi[INVESTIGATOR_35648], the study drug will 
be stopped. The explanation for stoppi[INVESTIGATOR_401571] , 
and the AE will be recorded and reported according to the AE reporting  guidelines. Participants 
will stop study drug, but data collection will continue as usual.  
 
7.[ADDRESS_506357] TO FOLLOW -UP 
The following actions will be taken if a participant is not able to be contact[CONTACT_401633] -up study visits:  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
34 • The study team will attempt to contact [CONTACT_401634]/or relative (s) in file and  to 
reschedule t he missed visit as soon as participant is available after the protocol -specific 
time window or perform a remote phone visit at the least.  
• Before a participant is deemed lost to follow -up, a study team member will make every 
effort to regain contact [CONTACT_190365] e participant and/or relative( s) in file (w here possible, 3 
telephone calls and, if necessary, a certified letter to the participant’s last known mailing 
address or local equivalent methods).  
 
Should the participant continue to be unreachable, EHR  will be reviewed to document 
participant’s vital status, and he or she will be considered to have withdrawn from the study with 
a primary reason of lost to follow -up. 
 
[ADDRESS_506358] between participants and non -clinical staff. Additionally, minimizing 
research activities and conducting the trial in a pragmatic manner will incr ease the ability to 
complete the trial in the face of strained clinical and research resources during the COVID -19 
pandemic. We will emphasize data that can be collected from the EHR , laboratory values as part 
of routine clinical care, and assessments that  can be completed over the telephone as needed.  
 
Medical History  
A complete medical history will be obtained from the EHR at the Screening Visit (Day 0) and 
any changes (i.e., adverse events) from the Baseline visit (Day 1) will be documented at every 
visit thereafter. The information will be recorded on the  REDCap  eCRF .  
 
Physical Examination  
A complete physical examination will not be performed if there is a documented physical 
examination by a physician or nurse practitioner provider in the EHR within 24 hours prior to 
consenting. The findings of the examination will be recorded on the eCRF and serve as baseline 
findings.  
 
Vital Signs  
Temperature, heart rate, oxygen saturation, respi[INVESTIGATOR_401572], and 
blood pressure will b e obtained at the screening visit and during every visit from the EHR. The 
results will be recorded on the REDCap eCRF.  
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506359] will be solicited from the participant or LAR.  
 
For the baseline visit, treatment intervention , and the follow -up visits, the following assessments 
will be c ompleted:  
 
Baseline variable collections:  
• Presence or absence of inclusion and exclusion criteria  
• Date and time of admission  
• Demographics (age, sex, race, and ethnicity)  
• Vitals and respi[INVESTIGATOR_108951]  
• Physical examination  
• Comorbidities  
• Acute signs and symptoms  
• Parameters to assess severity -of-disease using the Acute Physiologic and Chronic Health 
Evaluation ( APACHE ) II classification, as applicable  
• Current use of home and inhospi[INVESTIGATOR_401573] -the-counter    
• Receipt of open label stud y medication  
• Receipt of invasive procedures  
• Blood and urine collections and analyses ( see Table 4) 
• Other procedures as per the Schedule of Events ( see Section 1. 3 Table  1) 
 
Study intervention period (daily):  
• Date and time of randomization  
• Drug administration and accountability  
• Vitals and respi[INVESTIGATOR_108951]  
• Physical examination  
• Comorbidities  
• Acute signs and symptoms  
• Review of current medications  
• Receipt of invasive procedures  
• Hospi[INVESTIGATOR_401574], endpoints, and outcomes  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
36 • Collect hospi[INVESTIGATOR_401575] -II  
• Blood and urine collections and analyses  (see Table 4) 
• Other procedures as per the Schedule of Events ( see Section 1. 3 Table  1) 
 
Assessments following Hospi[INVESTIGATOR_3849] : Early discharge (before completing 10 -day 
intervention) and Follow -up visits  
 
Early discharge: Using daily phone call or videoconferencing , following data will be collected  
• Drug accountability  
• Vitals and respi[INVESTIGATOR_108951]  
• Comorbidities  
• Acute symptoms  
• Review current medications  
• Query about a dverse events, endpoints, and outcomes  
• Review EHR for additional data, if applicable  
• Fingerstick blood creatinine using the POC device will be performed by [CONTACT_2416]/care provider until Day 10  (see Table 4) 
• Daily urine collections for bio repository (see Table 4) 
• Blood collection will be done on Day 10 for research laboratory analysis and 
biorepository (see Table 4) 
• Other procedures as per the Schedule of Events ( see Section 1. 3 Table  1)  
 
Assessments for participants with early hospi[INVESTIGATOR_401576] a percentage of participants may be discharged home prior to 
completing 10 -day in hospi[INVESTIGATOR_336501]. In the event that participants will be discharged prior 
to the 10 -day study intervention days of study drug administration, the study drug will be 
provided to participants in a pi[INVESTIGATOR_401577] a 10 -day course. To monitor complian ce, at the time of discharge 
each participant will receive study drug administration and accountability log with instructions.  
 
In addition, to monitor pattern of fingerstick creatinine, each participant will be provided with a 
StatSensor Xpress®, a home fingerstick point of care (POC) device for fingerstick creatinine 
measurement. The device is similar to a glucose meter that utilizes a test strip and a small drop of 
blood from finger  stick . Participant and accompanying family member will receive a 
demonstration on how to use this device at the time of discharge along with lancets, alcohol 
swabs, test strips, and safe disposal biohazard waste containers. Using all safety measures, the 
study team will use the POC device using participant’s fingerstick blood. The POC device 
generated fingerstick creatinine value will be documented and compared with the discharge day 
routine serum creatin ine value. Participants will use POC fingerstick creatinine device daily for 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506360] urine and blood in compliance 
with all local and applicable COVID -19 safety measures.  
 
Follow up visits:  At each follow -up visit (Day 30 and Day 90), t he following assessments may 
occur at clinic or at home or by [CONTACT_401635] : 
• Review of current medications   
• Comorbidities  
• Record vital signs and physical examination  
• Collect data on adverse events, endpoints, and outcomes  
• Collect blood and urine for research laboratory analyses and biorepository  (see Table 4) 
• Other procedures as per the Sch edule of Events (see Section 1. 3 Table  1) 
 
Biospecimens Collections and Measurements  
 
Primary and secondary endpoints from routine daily laboratory tests and clinical care:  
 
Daily serum creatinine: Blood will be collected daily for the measurement of serum creatinine 
and documented for the study starting Day 1 and up to 10 days of hospi[INVESTIGATOR_401578]® for creatinine  and outpatient serum creatinine 
measurement for participants who will be discharged prior to the 10-day intervention period. 
There will be a serum creatinine measured on the 10th day for discharged participants, in addition 
to the StatSensor Xpress® finge rstick creatinine measurement.  AUC will be computed 
cumulatively across days for each patient . 
 
Daily urine output: Daily urine output will be reported as part of routine clinical care and 
documented for the study starting Day 1 and up to 10 days of hospit alization. Daily urine outputs 
will not be obtained for participants who will be discharged prior to 10 -day intervention period.  
 
Onset of dialysis: Timing of onset of dialysis will be reported as part of routine clinical care and 
documented for the study starting Day 1 and up to 10 days of hospi[INVESTIGATOR_059].  
 
Research Laboratory Biospecimens Collections for future Biomarkers Analysis :  
Blood and urine will be collected at Visit 1 and then every visit thereafter for secondary or sub -
study analyses. Baseline (Day 1) blood and urine collections will be performed before 
participants receive first study drug dosing and after obtaining consent. There will be additional 
blood and urine collections on Day [ADDRESS_506361] drug administrati on for 
pharmacokinetics and analyses  of biomarkers . Day 1 to Day 10 blood and urine collections will 
coincide with routine collection by [CONTACT_5035][INVESTIGATOR_33717]. Hospi[INVESTIGATOR_401579] -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506362] morning void urine into a 
provided container which will be kept refrigerated and pi[INVESTIGATOR_401580] (until Day 9) by [CONTACT_401636]. At Day [ADDRESS_506363] of research laboratory tests is provided 
in Table 4. 
 
Blood and urine collections on Day 30 ± 3 and Day 90 ± [ADDRESS_506364] when participants 
return to clinic or when the study team visits participants at home for follow -up visits. 
Collection, handling, and processing of all biospecimens will be performed in Biosafety 
Laboratory (BSL) 2 environment as per current US Centers for Disease Control and Prevention 
(CDC) guidance. Blood and urine biospecimens for analysis of biomarkers will be shipped to 
UTHSA and stored in a COVID -19 designated biorepository.   
 
All blood and urine biospecimens will be tracked in the REDCap study database. Biosamples 
will be reconciled with the study schedule of events to assure that all expected biosamples are 
accounted for. Study biosamples in the UTHSA COVID -19 designated biore pository will retain 
association with the clinical data.  
 
All assessments will be detailed in the MOP.  
 
8.2 SAFETY AND OTHER ASSESSMENTS  
 
Assuring participant safety is an essential component of this protocol. NR is considered GRAS 
(Generally Recognized as Safe) as filed for designation to FDA. Use of NR for the prevention 
and or treatment of AKI in COVID -19 positive participants, however, raises unique safety 
considerations. This protocol addresses these considerations through:  
• Exclusion crite ria designed to prevent potential overdose effects by [CONTACT_401637], nicotinamide, and NR ; 
• Daily  assessment of participants health status;  
• Systematic collection of safety outcomes;  
• Structured reporting of advers e events;  
• Appointment of independent safety adjudication committee (SAC)  
 
Study procedures and evaluations to be done as part of the study to monitor safety and support 
the understanding of the study intervention’s safety. For all visits starting from base line until the 
last follow -up visits, the following assessments will be completed:  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
39 • Physical examination: A physical examination at the baseline visit or a record of routine 
physical examination performed within 24 hours prior to consenting, and at Day 30,  and Day 
90 follow -up visits.  
• During the 10 -day intervention period, participant’s health status will be obtained on a daily 
basis from the participant and from EHR. Health status of participants will be collected by 
[CONTACT_401638] 30, and Day 90 f ollow -up visits. Participants will be specifically asked 
for any new symptoms on a daily basis.  
• The safety clinical laboratory parameters will be performed at each visit while hospi[INVESTIGATOR_057]. 
Any laboratory tests performed as part of routine clinical care (Clinical Laboratory Tests) 
within the specified visit window will be used for safety laboratory testing  (see Table 4) . 
 
Research laboratory tests : 
Blood for t he first whole blood NAD+ level will be drawn within [ADDRESS_506365] study 
drug dosing (i.e., baseline NAD+ level, Day 1). Whole blood NAD+ level will be measured daily 
for a total of 10 days while hospi[INVESTIGATOR_401581] .  
 
Safety  laboratory from routine daily laboratory tests:  
Safety laboratory will be performed at Visit [ADDRESS_506366] study drug dose will be accepted for the baseline (Day 1) safety laboratory tests. 
Any clinical laboratory tests (see Table 4) performed as part of routine clinical care within the 
specified visit can be used for safety laboratory testing within the per iod of hospi[INVESTIGATOR_83263] 
10 days prior to starting the study drug.  
 
Rationale for specific safety laboratory tests:  
Several case studies reported that COVID -19 patients may present with mild symptoms such as 
muscle weakness with elevated CPK  and laboratory confirmation of rhabdomyolysis [75-77]. 
Although, the incidence of rhabdomyolysis in COVID -19 is not known, several case reports 
indicate an association between rhabdomyolysis and AKI in COVID -19 patients  [78-80]. One 
study reported elevated levels of CPK in about 14% of patients [21], suggesting involvement of 
muscle injury.  
 
NR has been evaluated on the development of aging -induced non -alcoholic fatty liver disease in 
mice [81]. It was found that AST (aspartate transaminase) level was significantly reduced by [CONTACT_401639] (ALT) level decreased without significance 
compared to baseline [81]. One human study demonstrated that NR significantly reduced AST 
level at day 56 from baseline [8]. It is likely that COVID -19 patients will be receiving different 
medications for comorbidities and as per the FDA guidance [82], liver function tests will be 
performed as listed in the  Table 4.  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
40 Table 4: Blood and urine tests for research  laboratory , safety , and repository  
 
Research laboratory tests  Safety  laboratory tests  Repository  
Daily during Study Day 1 to Study Day 10   
Blood  (daily) : 
1. Whole blood NAD+  
2.  Serum creatinine 
(performed if 
routine test is 
missed or not 
available)  
 
Urine  (daily) :  
1. Urinalysis  
2. Urine creatinine  
3. UACR and UPCR  
4. Urine glucose  
5. Lactate  
6. Urine phosphate  
7. Urine NAD+ 
metabolome  
 Blood:  
1. CPK on day 5  
2. Liver function tests on day 5  
3. Daily CBC and platelets 
(performed if routine test is 
missed or not available)  
 Blood:  
• Future biomarkers  
• Genetic analysis  
 
Urine:  
• Future biomarkers  
 
Note : additional collections at 
hour [ADDRESS_506367] -
randomization  study drug for 
PK analysis  
Day 30 and Day 90  
Blood:  
1. Serum creatinine  
2. Whole blood NAD+  
3. Serum electrolytes 
(Na, Cl, K)  
4. Bicarbonate  
5. Calcium and 
phosphate  
6. Blood glucose  
7. CBC with platelets   
 
Urine:   
1. Urinalysis  
2. Urine creatinine  
3. UACR and UPCR  
4. Urine glucose  
5. Lactate  
6. Urine phosphate  
7. Urine NAD+ 
metabolome   
 Blood:  
• Future biomarkers  
• Genetic analysis  
 
Urine:  
• Future biomarkers  
 
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506368] interactions with the participants, safety assessment s will be performed by 
[CONTACT_401640], participant interviews, vital sign measurements, physical examination, 
and laboratory tests, including complete blood count and comprehensive metabolic panel , and 
diagnostic tests or procedures . Participants ’ reported symptoms or complaints recorded in the 
medical record will be reviewed  and recorded in the appropriate eCRF . In addition, information 
will be solicited from the participants and designated staff physicians to supplement accurate and 
complete safety  assessment .  
 
Each participating investigator will have primary responsibility for the safety of the individual 
participants under his or her care. The investigators will determine daily if any adverse events 
occur during the period from enrollment throug h study intervention and will determine if such 
adverse events are reportable. Thereafter, adverse events will not be required to be reported 
unless the investigator feels the adverse event was related to the study drug or study procedures.  
 
The site investigator will (i) provide a verbatim term (a diagnosis where possible) for detected 
and reportable AE, (ii) each AE will also be described in terms of duration (start and stop date), 
severity, association with the study product, action(s) take n, and outcome , (iii)  classify and 
assign a grade to each detected and reportable adverse event using the CTCAE v. 5.0 
classification system, and ( iv) rate the likelihood that the event was related to the study drug.  
 
A team of medical monitors (Safety Adjudication Committee, SAC), composed of three 
clinicians with expertise in infectious disease or acute care management, one from each study 
site, independent of the study investigators will review the medical charts for  unexpected AE 
/SAE data weekly during the study intervention period . The senior SAC member will serve as 
SAC Chair. The SAC will  confirm the verbatim term (a diagnosis where possible) for detected 
and reportable adverse event with knowledge of the study site physician’s rating  and then 
classify and assign a grade to each detected and reportable adverse event using the CTCAE v. 5.0 
classification system. Disagreements between the study site investigator and the SAC member 
will be adjudicated weekly on a call facilitated by [CONTACT_401641] .  
 
All A Es will be recorded on the AE eCRF.  Verbatim terms for A Es will be coded to the current 
version of the MedDRA coding dictionary at the DCC . Verbatim terms will be coded at the 
Lower Level Term (LLT) where possible and to the Preferred Term (PT) otherwise. Accurate 
mappi[INVESTIGATOR_401582]. A Es and SAEs will be 
aggregated and reported for the DSMB at the PT level. If the SAC identifies an unexpected SAE, 
sIRB and FDA expedited reporting  procedures  will be followed and the DSMB will be notified.  
 
8.3 ADVERSE EVENTS AND S ERIOU S ADVERSE EVENTS  
   
8.3.1  DEFINITION OF ADVERSE EVENTS  (AE)  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506369] medical occurrence associated with the use of an 
intervention in humans, (which may cause worsening of a pre -existing medical condition),  
whether or not it is considered intervention -related [FDA (21 CFR 312.32 (a)) ].  
 
Any medical condition that is present at the time participant  provide d consent to the protocol will 
be considered  as baseline and not reported as an AE. However, if the severity of any pre -existi ng 
medical  condition increases  after consenting , it will be recorded as an AE.  
 
Given the nature of severity and unpredictable clinical course and outcomes of the underlying 
illness, participants  will have many symptoms and  abnormalities in health or vital  status  and 
laboratory  findings . All Grade 3 and 4 A Es will be captured as A Es in this  trial. These grades are 
according to the CTCAE (Common Terminology Criteria for Adverse Events, Version 5.0, 
November 27, 2017. U.S. Department of Health and Human Servi ces, National Institutes of 
Health).  
 
8.3.2  DEFINITION OF SERIOUS ADVERSE EVENTS  (SAE)  
 
An SAE is defined as “An AE or suspected adverse reaction is considered serious if, in the view  
of either the investigator or the sponsor, it results in any of the following outcomes:  
 
• A life -threatening AE;  
• New hospi[INVESTIGATOR_26109] p rolongation of existing hospi[INVESTIGATOR_059];  
• A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions,  
• Death , 
• Any other event requiring medical or surgical treatment to prevent one of the outcomes 
above  
 
All SAEs, as with any AE, will be assessed for severity and relationship to study intervention. 
All SAEs will be recorded on the appropriate SAE eCRF. All SAEs will be followed t hrough 
resolution or stabilization by a licensed study physician (for IND studies, a physician listed on 
the Form FDA 1572 as the site PI [INVESTIGATOR_54720] -Investigator).  
 
In this protocol , other safety events will be defined as follows:  
 
Suspected Unexpected Serious  Adverse Reaction ( S[LOCATION_003]R): An adverse reaction that is both 
unexpected (not consistent with risks outlined in the study protocol), serious, and meets the 
definition of a suspected adverse reaction.  A Serious Unexpected Serious Adverse Reactions 
(S[LOCATION_003]R) is any SAE where a causal relationship with the study product NR is at least 
reasonably possible but has not been documented in currently available  published reports or data. 
In making this assessment , there should be consideration of the probability of an alternative 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
43 cause (for example, COVID -19 itself or some other pre -existing conditions or comorbidities 
preceding randomization), the timing of the event with respect to study treatment and the 
respon se to withdrawal of the study treatment.  
 
8.3.3  CLASSIFICATION OF AN ADVERSE E VENT  
[IP_ADDRESS]  SEVERITY OF EVENT  
 
In the protocol, the following guidelines will be used to describe severity of adverse events :  
• Mild (Grade 1): Events require minimal or no treatment and do no t interfere with the 
participant’s daily activities.  
• Moderate (Grade 2):  Events result in a low level of inconvenience or concern with the 
therapeutic measures. Moderate events may cause some interference with functioning.  
• Severe (Grade 3):  Events inter rupt a participant’s usual daily activity and may require 
systemic drug therapy or other treatment. Severe events are usually potentially life -
threatening or incapacitating. Of note, the term “severe” does not necessarily equate to 
“serious”.  
• Severe (Grade  4): Events that are potentially life threatening.  
• Death (Grade 5)  
 
[IP_ADDRESS]  RELATIONSHIP TO STUDY INTERVENTION  
 
Study investigators will grade the strength of the relationship of an adverse event to study drug 
or study procedures as follows:  
• Definitely Related : The event follows: a) A reasonable, temporal sequence from a study 
procedure; and b) Cannot be explained by [CONTACT_82977] ’s 
clinical state or other therapi[INVESTIGATOR_014]; and c) Evaluation of the participants ’ clinical state 
indicates to the investigator that the experience is definitely related to study procedures.  
• Probably or Possibly Rel ated: The event should be assessed following the same criteria 
for “Definitely Associated”. If in the investigator’s opi[INVESTIGATOR_401583], then “probably” or “possibly” associated should be selected.  
• Probably Not Rel ated: The event occurred while the participant  was on the study but can 
reasonably be explained by [CONTACT_82977] ’s clinical state or 
other therapi[INVESTIGATOR_014].  
• Definitely Not Related : The event is definitely produced by [CONTACT_2299] ’s clinical state 
or by [CONTACT_401642] . 
• Uncertain Relationship : The event does not meet any of the criteria previously outlined.  
 
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
44 [IP_ADDRESS]  EXPECTEDNESS  
 
The study investigators will be responsible for determining whether an AE is expected or 
unexpected. An AE will be considered unexpected if the nature, severity, or frequency of the 
event is not consistent with the risk information previously described for the study intervention  
and hospi[INVESTIGATOR_2779] . 
8.3.[ADDRESS_506370] all events with start dates occurring any time after 
informed consent is obtained until Day 90 – the last visit . The study investigator  will review 
EHR daily to collect and assess all A Es (including SAEs) from the time participants provided 
consent to the study until Day 10  and again during Day 30 and Day 90 follow -up visits 
regardless of its relationship to study drug . At each visit, the investigator will inquire about the 
occurrence of any new and the prognosis of already documented AE/SAEs since the last visit. 
All A Es will be captured  in detail  and followed to satisfactory  resolution  or stabilization , until 
the in vestigator  deems the event chronic  or not clinically significant  and until the participant is 
considered to be stable.  The participants will receive standard of care for the event s. Site 
investigator s will consult with treating physician to monitor  the event progression. Study 
investigators will also assess if there is a r easonable possibility that the study drug or procedure 
caused the event. Investigators will also consider if the event is explained by [CONTACT_2299]’s 
underlying medical conditions, anticipated clinical course, previous medical conditions, and 
concomitan t medications.  
 
Routine and safety laboratory values from the respective hospi[INVESTIGATOR_401584]. 
Participants will receive standard of care for the event and followed to satisfactory resolution or 
stabilization, The DCC will review laboratory results for completeness. Any abnormal laboratory 
test results (clinical chemistry, hematology, or urinalysis) or other safety assessment (e.g., CPK), 
including those that worsen from the baseline, felt to be clinically significant in the medical and 
scientific judgement of the investigator, will be recorded as AEs. The SAC will review AEs 
weekly and SAEs on a daily basis and any events that the clinical c enters categorize as requiring 
treatment discontinuation for safety reasons . 
  
The following laboratory results will be flagged as expected study A Es in this trial:  
• Thrombocytopenia: Platelet count >25% reduction from the baseline ; 
• Liver function test abno rmalities: AST, ALT, total bilirubin, alkaline phosphatase > 4 
times the upper limit of normal ; 
• Creatinine phospho kinase  (CPK):  > 4 times upper limit of normal ; 
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
45 The following symptoms will be flagged as expected study A Es in this trial : 
• Bruising  
• Bleeding  
• Severe diarrhea  
• Severe nausea  
• Flushing  
• Hives  
• Heartburn.  
 
8.3.[ADDRESS_506371] NR (i.e. new side effects or increasing 
frequency of side effects) will be reported to SAC on weekly basis. Significant no n-clinical 
findings will also be reported to SAC if they are suggestive of increased risk for study patricians.  
8.3.6  SERIOUS ADVERSE EVENT REPORTING  
 
The study investigators will report all  unexpected  serious adverse events  and t heir relatedness to 
study drug or procedure to the DCC within 24 hours of awareness or initial assessment . The 
DCC will then notify the sIRB and NIDDK . These reporting will follow the criteria outlined in 
21 CFR 312.32(c). The SAC will be blinded  to the randomization code  and will determine if the 
event is unexpected and define the relationship to NR based on section [IP_ADDRESS] . An adverse  event  
is considered “unexpected” if it is not listed in the study protocol (21 CFR 312.32(a)). If a 
determinatio n is made that a serious adverse event which is not exempt and has a reasonable 
possibility of having been caused by a study procedure or the study drug, it will be classified as a 
suspected adverse reaction. If the suspected adverse reaction is unexpected , it will be classified 
as a S[LOCATION_003]R.  
 
The DCC will report all unexpected deaths, serious and treatment related adverse events, and 
S[LOCATION_003]Rs to the DSMB  and NIDDK within 7 working days after receipt of the report from a 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
46 clinical site. A written report will be sent to the DSMB, FDA, local IRB, and the sIRB within 15 
calendar days. The DSMB will also review all reported adverse events and clinical outcomes 
during scheduled DSMB meetings. The DCC will distribute the written summary of the DSMB’s 
periodic review of  reported adverse events to the local IRB and sIRB in accordance with NIH 
guidelines ( http://grants.nih.gov/grants/guide/notice -files/not99 -107.html ).  
 
In addition, (1) serious, unexpected suspected adverse reactions, (2) findings  
from other clinical, animal, or in -vitro studies that suggest significant human risk,  
and (3) a clinically important increase in the rate of a serious suspected adverse  
reaction will be reported to all investigators, sIRB, local IRB, the FDA, and the DSMB no later 
than 15 calendar days after determining that the information qualifies for reporting [21 CFR 
312.32(c)(1)].  
 
Clinical Outcomes that will be Ex empt from Serious Adverse Event Reporting  
 
Pre-specified laboratory safety endpoints will be design ated to evaluate possible laboratory  
abnormalities that might be seen with NR based on previous studies with NR (i.e., <10% 
reduction in hemoglobin and >25% reduction in platelet counts from baseline ). 
 
Study -specific outcomes of COVID -19 infection and critical illness will be systematically 
collected for all participants in both study group and are exempt from adverse event reporting 
unless the investigator considers the event to be Definitely or Possibly Related (or of an 
Uncertain Relationship  – section [IP_ADDRESS] ) to the study drug or study procedures. Examples of 
study -specific clinical outcomes include:  
• Death not related to the study procedures  
• Cardiovascular events  
o Receipt of vasopressors  
o Atrial or ventricular arrhythmia  
o Cardiac arrest  
o Respi[INVESTIGATOR_29343]   
o Hypoxemia requiring supplemental oxygen  
o Acute respi[INVESTIGATOR_1505]  
o Receipt of mechanical ventilation  
o Receipt of extra -corporeal membrane oxygenation  
• Gastrointestinal events  
o Elevation of aspartate aminotransferase or alanine aminotransferase  
o Acute pancreatitis  
o Severe diarrhea  
• Hematological events  
o Anemia  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
47 o Thrombocytopenia  
 
Note: A study -specific clinical outcome may also qualify as a reportable adverse event.  
 
8.3.7  EVENT ADJUDICATION PROCESS   
 
Unexpecte d AEs and SAEs occurring from the time the informed consent signed through the 
Day 90 visit will be documented, recorded, and reported. Upon entry into REDCap  eCRF , a 
notification will be generated to the independent site SAC member that unexpecte d AEs are 
ready for review. SAC members will be expected to review unexpecte d AEs within one week of 
notification. ( Unexpected SAEs will have different language in the text  and will require same 
day review by [CONTACT_401643].) SAC review will be separate from the expedited SAE reporting 
process and incomplete SAC assessment will in no way delay expedited SAE reporting.  
 
Adjudicators will be blinded to the study treatment actually given to each patient and will use 
subject matter knowledge to render opi[INVESTIGATOR_401585], for example, relatedness to treatment.  
The database will be configured so that certain baseline data will be viewable, including age, 
race, gender , BMI, diabetic status (diabetic, not diabetic), and current smoking status (smoker, 
not a smoker).  
 
The REDCap adjudication module will compare the site investigator’s AE grade and relatedness 
with that of the independent site SAC Physician. Where they ag ree, no further action will be 
needed  and the AE will be submitted to statistician for reports to DSMB . Where the independent 
site SAC Physician  disagrees with site investigator’s AE grade and relatedness , the site 
investigator will be notified to review t he report. Where the site investigator and independent 
SAC member agree , AEs that are not also other reportable events will be considered complete . 
AEs meeting the definition of other reportable events such as SAEs will trigger those processes 
with automat ed system notifications. Where the site investigator and independent SAC member 
disagree, the AE will be labeled as needing adjudications. Weekly adjudication meetings will be 
held if there are unexpecte d AEs needing adjudication. The study investigator wi ll work 
collaboratively with the SAC on adjudication calls to make a final determination if an adverse 
event or reaction has a reasonable possibility of having been caused by [CONTACT_401644] 21 CFR 312.32(a)(1). The protocol for handling of unexpecte d AEs and 
SAEs which are not uniformly adjudicated will be established.  Any change to an adjudicated AE 
by a site investigator or SAC member will trigger review by [CONTACT_401645]. Where changes impact t he adjudication decision, the event will be triggered for re -
adjudication by [CONTACT_401646]. The Adjudication process will be tracked and managed by [CONTACT_401647] . AEs will be summarized for the DSMB as described in the 
DSMB plan . 
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506372]  
 
Not-applicable.  
 
8.3.10  REPORTING OF PREGNANCY  
 
Not-applicable.  
 
8.4 UNANTICIPATED PROBLEMS  
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
An Unanticipated Problem (UP) is any event, incident, experience, or outcome that meets the  
following criteria:  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures  
that are described in the protocol -related documents, such as the IRB -approved research  
protocol and informed consent document; and (b) the characteristics of  the participant  
population being studied;  
• Related to participation in the research (meaning there is a reasonable possibility that the  
incident, experience, or outcome may have been caused by [CONTACT_401648]); and  
• Suggests that the  research places participants  or others at a greater risk of harm (including  
physical, psychological, economic, or social harm) than was previously known or  
recognized.  
 
8.4.2   UNANTICIPATED PROBLEM REPORTING  
 
All unanticipated problems will be collected and defined as per the Unanticipated Problems 
Involving Risks & Adverse Events Guidance (2007) – HHS regulations at 46.103(b)(5).  
 
To satisfy the requirement for prompt reporting, UP will be reported  
using the following timeline : 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
49 • UPs that are SAEs will be reported to the sIRB, local IRB, and the SAC within 24 hours of 
the investigator becoming aware of the event per the SAE reporting process  describe d above . 
• Any other UP will be reported to the sIRB, local IRB, and the SAC within 3 days of the 
investigator becoming aware of the problem.  
 
As per the FDA guidelines [21 CFR 312.32(c)(2)], any unexpected fatal or life -threatening 
suspected adverse reactions to study active agent will be reported to the sIRB, local IRB, FDA, 
and DSMB no later than 7 calendar days after initial receipt of the information.  
 
8.4.3  REPORTING UNANTICIPATED PROBLEMS  TO PARTICIPANTS  
 
Not-applicable.  
 
9 STATISTICAL CONSIDERATIONS   
  
9.1 STATISTICAL HYPOTHESES  
 
The primary analysis will perform a two -sided α = 0.[ADDRESS_506373] of the null hypothesis of no 
difference in mean whole blood NAD+ level changes from the baseline and day [ADDRESS_506374] a 
different mean change than those randomized to placebo ..  
 
9.2 SAMPLE SIZE  DETERMINATION  
 
We evaluated using a marker of efficacy for NR with the whole blood NAD+ based on two 
recent publications [8, 15]. In a study of healthy overweight subjects 40 -60 years of age, Conze 
et al. [8] found a 21 µg/ml mean NAD+ diff erence between patients randomized to 1000 mg 
NIAGEN versus those randomized to placebo at day 7 (NIAGEN 42 µg/ml, Placebo 21 µg/ml) 
with a standard deviation of 10 µg/ml and approximately equal baseline means (NIAGEN 21 
µg/ml, Placebo 24 µg/ml).  Simic et  al. [15] assessed a combination of NR with pterostilbene 
(NRPT) vs placebo in hospi[INVESTIGATOR_401530] ≥ 18 years with AKI and found an 18% 
increase in whole blood NAD+ within 48h post treatment in the NRPT grou p, and a 50% 
reduction from baseline in the placebo group with AKI. With reference to Conze et al. [8] al., 
this study will achieve >99.9% power for testing H o:RNR = R Placebo  versus H o: RNR≠RPlacebo  with 
alpha=0.05, autocorrelation ( )=0.5, and n=[ADDRESS_506375] to NAD+.  In this setting the effect 
size is 2.1 [=(42 -21)/10] and the minimally detec table effect size is 0.63 . 
 
 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506376] deviation, median, minimum, and maximum. Categorical and binary data will be 
summarized with frequencies and percentages. Raw data storage, documentation, and  security 
will be effectively served with the REDCap platform. Participants will be randomized to 
treatments in randomly permuted blocks of size 2 and 4 stratified by [CONTACT_68566].   
 
The number of participants screened, the number of screen failures by r eason, and the number 
eligible for randomization, the number randomized, and, by [CONTACT_3148] (Placebo, NR), the number 
withdrawing from the study for any reason, lost to follow -up by [CONTACT_48933], unable to receive at least 
one dose and replaced, and the number co mpleting the study per protocol will be tabulated and 
summarized with a CONSORT Diagram. We will also describe adherence to treatment over the 
course of the study, overall and by [CONTACT_2939].   
 
Randomized controlled trials often suffer from two major co mplications, i.e., noncompliance and 
missing outcomes. One potential solution to this problem is a statistical concept called intention -
to-treat (ITT) analysis, to be used in this trial. ITT analysis includes every subject who is 
randomized according to ra ndomized treatment assignment. It ignores noncompliance, protocol 
deviations, withdrawal, and anything that happens after randomization. ITT analysis maintains 
prognostic balance generated from the original random treatment allocation. In ITT analysis, 
estimate of treatment effect is generally conservative [83].  
 
Missing data can threaten the inferences made about study questions. The study team will make 
every effort to minimize the impact of missing data, including attempting to obtain final 
information o n participants even if adherence to study procedures is poor or they do not follow 
the randomized treatment. In cases where missing data is unavoidable, we will use multiple 
imputation using chained equations to impute outcomes and relevant covariates to m itigate the 
potential impact of missing data, combining across imputations with Rubin’s rules to account for 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
51 the variability in the imputation procedure [84]. Any data point that appears erroneous or 
inexplicable based on clinical judgement will be investi gated by [CONTACT_464]. If data points are 
considered to be outliers then sensitivity analyses will be carried out with and without the 
suspected outlier. Under the missing at random (MAR) assumption the estimates provided by [CONTACT_401649] [85].  
 
All data will be summarized by [CONTACT_401650].  
Statistical estimates of treatment effects (with 95% confidence interva ls, where appropriate), and 
p-values will be tabulated. All statistical tests will be two -sided with a significance level of 5%.  
R and/or SAS will be used throughout. Due to the overall exploratory nature of this study 
corrections for multiple comparisons  will not be applied . 
  
9.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
 
PRIMARY END POINT: Blood NAD+ level  
 
The null hypothesis to be tested is H o:RNR=RPlacebo , where R NR and R Placebo  are the rates of change 
from baseline to day [ADDRESS_506377] that the rate of change in 
NAD+ from baseline to day10 with NR treatment will be increased relative to Placebo.  Whole 
blood NAD+ will be measured daily in each patient during the first 10 days upon randomization. 
NAD+ level changes from the  baseline will be graphically summarized with overlaid line and 
whisker plots of the mean trajectory for each arm with the whiskers being of length equal to one 
standard error of the mean. The significance of treatmement group differences with regard to th e 
rate of change of NAD+ will be assessed using the methods of Schluchter et al [86] to address 
informative censoring, due for example to dialysis and death, with a random subject effect to 
account for the correlation among repeated measures within an indi vidual. The model will 
include treatment and day.  The day by [CONTACT_401651]. Adjusted analyses will be carri ed out with age, race, clinical site, baseline 
serum creatinine, treatment and day included in the model. The unadjusted and adjusted models 
will be summarized with the coefficients, standard errors, 95% confidence intervals and p -
values. A day by [CONTACT_22058] t interaction term, treatment by [CONTACT_4475], and treatment by [CONTACT_401652] (p<0.10). We will 
examine potential treatment interactions among subgroups of interest such as age, and sex . 
Consistent with the power calculation (Section 9.2), these models will be used to provide 
treatment group contrasts on the mean rate of change (estimated by [CONTACT_401653], also known as the slope parameter), summarized with the mode l-based mean rates of 
changs, mean differences in rates of change and 95% confidence intervals and p -values.  
Spaghetti plots and plots of the mean NAD+ trajectories by [CONTACT_1570], and mean rates of 
change, will be reported.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506378] of care, pre-existing CKD, and treatments by [CONTACT_30157] (NR, 
Placebo) may be used to define other potential adjustments with binary or categorical variables 
to be defined post hoc in exploratory analyses. Such models may motivate extended 
interpretations of any trea tment effects found.  
 
PRIMARY END POINT: Safety  
 
All reportable AEs will be listed by [CONTACT_401654], treatment, clinical site, grade, 
relation to treatment, severity, and seriousness. All unanticipated events will be listed by 
[CONTACT_401655] a detailed description of each event, incident, experience or 
outcome.  An unblinded statistician will summarize safety data periodically for the DSMB.  
 
AEs will be tabulated by [CONTACT_401656], displaying, for each event, the number and 
percentage of participants experiencing at least one Grade 3 or 4 occurrence and he null 
hypothesis to be tested is H o: pNR=pPlacebo  where p NR and p Placebo  are the probabilities of 
experiencing at leat one Grade 3  or Grade 3 event in the NR and Placebo groups.  H o will be 
tested with Fisher’s Exact test, overall and by [CONTACT_68566].  Additionally, treatment groups will 
be contrasted on the occurrence at least once of each event with Fisher’s exact test. All statis tical 
testing will be two -sided with a significance level of 5%.  
 
9.4.3  ANALYSIS OF THE SECONDARY ENDPOINT(S)  
 
SECONDARY END POINT:  AUC Serum creatinine over [ADDRESS_506379] that rate of change in AUC serum creatine wil l be decreased in the NR group relative 
to the Placebo group.  The null hypothesis to be tested is H o:RNR=RPlacebo , where R NR and R Placebo  
are the rates of change in serum creatinine from baseline to day [ADDRESS_506380] error of the mean.  To address non -ignorable missingness due to 
dialysis, death, or withdrawal of consent, all of which may be considered as informative 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
53 censoring, the statistical method will be the same as that specified for NAD+.   Potential 
participants who may have severe AKI or advanced CKD will considered with a binary 
independent variable in the models addressing this condition with corresponding displays of the 
line and whisker plots by [CONTACT_401657] c oefficients, standard errors 
and p -values. Interactions between this binary variable and treatment will be of interest and will 
be described.  
 
SECONDARY END POINT: Serum creatinine AUC and ordinal categorical outcome with 
four categories including dialysis  and death  
 
Serum creatinine AUC will be computed using the trapezoidal rule within each patient starting 
from randomization to day 10, and will be assigned to Category 1 if AUC < median AUC, to 
Category 2 if AUC ≥ median AUC in those who do not experience  dialysis and who do not die 
during the first [ADDRESS_506381] 10 days of 
hospi[INVESTIGATOR_401586] d to Category 4.  The null hypothesis is H o: OR 1=OR 2=OR 3=1, 
where OR 1, OR 2, and OR 3 are the odds ratios for Categories 1, 2, 3, and 4.  If the proportional 
odds model holds the null hypothsis is H o:OR=[ADDRESS_506382] that the odds of Category 1 will be inc reased, 
the  odds of Category 2, 3, and 4 will be decreased.  
 
The primary analysis will be based on a cumulative logit model for ordinal data of the primary 
outcome with terms for treatment, age, gender, clinical site, and baseline serum creatinine. The 
proportional odds assumption will be tested with a score statistic and empi[INVESTIGATOR_401587]. If the 
proportional odds assumption is violated then the analysis will be conducted under a partial 
proportional odds assumption. Under a partial proportional odds assumption, three odds ratios 
will be estimated; if evidence suggests that the proportional odds assumption holds, a single odds 
ratio will summarize the treatment effect. In either case, the odds ratio estimate(s), 95% 
confidence interval(s), and p -value( s) will be reported. Further study will be indicated if the p -
value for any treatment effect suggesting benefit in the NR arm is less than or equal to 0.05.  
 
SECONDARY END POINT:  Major Adverse Kidney Events (MAKE)  
 
The null hypothesis is H o:HR=[ADDRESS_506383] that HR will be less than 
1.  MAKE is defined as Yes if a doubling of serum creatinine (from baseline), the initiation of 
long-term dialysis, or d eath from any cause is observed, and No otherwise. Treatment arms will 
be compared with regard to the time to the first occurrence of MAKE over the entire duration of 
the study from baseline to [ADDRESS_506384] models of time 
to MAKE in terms of treatment without and with adjustment for age, race, clinical site, baseline 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506385] errors and 95% confidence intervals and 
corresponding hazard ratios will be reported without and with adjustmen t for covariates. The 
proportional hazards assumption will be assessed with Schoenfeld residuals and log survival 
plots. The unadjusted model will be graphically summarized with overlaid Kaplan Meier curves 
and the p -value for the corresponding log rank te st. Covariate interactions with treatment will be 
of interest and will be explored.  
 
SECONDARY END POINT: Kidney impairment as indicated by [CONTACT_401604] 
30 and 90 days  
 
The null hypothesis to be tested is H o: RNR=RPlacebo, where R NR and R Placeb o are the mean rates of 
change of eGFR in patients randomized to NR or to Placebo respectively from baseline to day [ADDRESS_506386]-randomization, measured by 
[CONTACT_401658] -EPI (the Chronic Kidney Disease Epi[INVESTIGATOR_10444]) 
equation [87] and the urine protein/creatinine ratio (PCR). To address non -ignorable missingness 
due to dialysis, death, or withdrawal of  consent, all of which may be considered as informative 
censoring, the statistical method will be the same as that specified for NAD+.  
 
eGFR will be evaluated untransformed, while urine PCR will be log -transformed to evaluate 
percent change because urine P CR is highly skewed and relative changes in urine PCR are 
proportional to risk of adverse renal and cardiovascular outcomes. We will include time, 
treatment, and interactions of treatment with time as independent variables in a mixed effects 
linear model. We will focus on the coefficient for the interaction of treatment with time as the 
primary measure of treatment effect. We will consider a p -value <0.[ADDRESS_506387]. These analyses will be further ad justed for baseline 
characteristics that are prognostic of the outcome, including age, sex, clinical site, and stage of 
AKI at randomization. Adjustment will be accomplished by [CONTACT_401659].  
 
9.4.4  SAFETY ANALYSES  
 
Please see section 9.4.2  ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT  
 
9.4.5  BASELINE DESCRIPTIVE STATISTICS  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506388] to 
demographic characteristics (age, race, ethnicity, and gender) , and clinical, laboratory and 
questionnaire measurements of efficacy ( Section 8.1 ). 
 
9.4.6  PLANNED INTERIM ANALYSES  
An O'Brien -Fleming procedure will be used to conduct an interim analysis for safety when 50% 
of the patients complete the study. A statistical b asis for stoppi[INVESTIGATOR_401588] (the occurrence of at least one 
serious adverse event of grade 3 or higher or the occurrence of thrombocytopenia less than 
50,000 per micro liter) indicates harm in the NR arm at p≤0.003. If the test statistic does not reach 
p≤0.[ADDRESS_506389] look then the trial will proceed to the final analysis. The statisticians (Drs. 
Joel Michalek and Leila Zelnick) will inform the principal investigato r if the interim analysis 
crosses the boundary in the direction of harm is observed (p≤0.003). A treatment effect will be 
declared harmful at the final analysis if the test statistic indicates harm and p≤0.047. The safety 
data will be summarized at interim  analysis. The statisticians will inform the DSMB if there are 
any safety concerns at the interim analysis. Any decision on stoppi[INVESTIGATOR_401589] . 
9.4.7  SUB -GROUP ANALYSES  
 
Not applicable.  
 
9.4.8  TABULATION OF INDIVIDUAL PARTICIPANT  DATA  
 
Not applicable.  
 
9.4.9  EXPLORATORY ANALYSES  
 
EXPLORATORY END POINT S:    
Correlations between whole blood NAD+, AUC serum creatinine, and surrogate markers of 
AKI (such as KIM -1 and NGAL) will be quantified with Pearson or Spearman correlation 
coefficients, 95% confidence intervals and p -values and visualize with scatter plots and 
overlaid least square lines.  Relationships between these variables by [CONTACT_401660].  Principal component analyses may be used.  Data may be log transformed prior to 
analysis and graphics . 
    
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
 
10.1 REGULATORY, ETHICA L, AND STUDY OVERSIGHT CONSIDERATIONS  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
56  
10.1.1  INFORMED CONSENT PROCESS  
  
 
[IP_ADDRESS]  CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS  
 
This study will be conducted in conformity with the principles set forth in The Belmont Report:  
Ethical Principles and Guidelines for the Protection of Human Participants of Research (US  
National Commission for the Protection of Human Participants of Biomedical and Behavioral  
Research; April 18, 1979), and the federal policy for the Protectio n of Human Participants 
codified in 45 CFR Part 46, 21 CFR Part 50 (Protection of Human Participants), and the ICH E6 
(R2).  
 
Each institution engaged in this research will hold an OHRP -approved FWA. sIRB will review 
and approve this protocol, associated in formed consent documents, recruitment material, and 
handouts or surveys intended for the participants, prior to the recruitment, screening, and 
enrollment of participants. The sIRB review shall be in accordance with 45 CFR 46 and 21 CFR 
50, 21 CFR 56 (IRBs ), and other federal, state, and local regulations and policies, as applicable. 
Local site IRBs may have additional national and local regulations.  
 
Any amendments to the protocol or consent materials will be approved by [CONTACT_401661]. sIRB review and approval will occur at least 
annually throughout the duration of the study. The investigator will notify the sIRB of any 
deviations from the protocol and SAEs, as applicable to the sIRB policy.  
 
[IP_ADDRESS]  CONSENT PROCEDURES AND DOCUMENTATION  
 
Consent forms describing in detail about the study intervention, study procedures, and risks are 
given to the participant and written documentation of informed consent is required prior to 
starting intervention/admini stering study intervention. Informed consent is a process that is 
initiated prior to an individual agreeing to participate in a trial and continuing throughout the 
individual’s trial participation. Investigators or designated research staff will obtain a 
participant’s informed consent in accordance with the requirements of 45 CFR 46, 21 CFR 50 
and 21 CFR 56 for FDA -regulated studies, state and local regulations and policy, and ICH E6 
GCP before any study procedures or data collection are performed. All cons ent forms will 
receive prior approvals from sIRB followed by [CONTACT_240825]/hospi[INVESTIGATOR_401590].  
 
Typi[INVESTIGATOR_897], participants or their LAR receive a concise and  focused presentation of key 
information a bout the clinical trial, verbally and with a written  consent form. Participants (or 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
57 LAR) must sign the ICF prior to starting any study procedures being done specifically for this 
trial. Once signed, a copy of the ICF will be given to the participant  or the  LAR for their records.  
 
Many of the participants  approached for participation in this research protocol will have 
impaired decision -making capacity due to critical illness and will not be able to provide informed 
consent. Accordingly, informed consent wil l be sought from the participant’ s LAR. Regarding 
consent from the LAR, the existing federal research regulations (‘the Common Rule’) states at 
45 CFR 46.116 that “no investigator may involve a human being as a subject in research…unless 
the investigator h as obtained the legally effective informed consent of the subject or the subject’s 
legally authorized representative”; and defines at 45 CFR 46 102 (c) a LAR as “an individual or 
judicial or other body authorized under applicable law to consent on behalf o f a prospective 
subject to the subject’s participation in the procedures(s) involved in the research.” The Office of 
Human Research Protections (OHRP) defined examples of “applicable law” as being state 
statutes, regulations, case law, or formal opi[INVESTIGATOR_1101]  a State Attorney General that addresses the 
issue of surrogate consent to medical procedures. Such “applicable law” could then be 
considered as empowering the LAR to provide consent for participant participation in the 
research. Interpretation of “applica ble law” may be state specific and will be addressed by [CONTACT_401662].  
 
Participants for whom consent was initially obtained from a LAR, but who subsequently regain 
decision -making capacity while in the hospi[INVESTIGATOR_401591], including continuance of data acquisition. The consent form signed by [CONTACT_401663].  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’s study participation. Conse nt forms will be 
Institutional Review Board (IRB) -approved. Due to the unique challenges of COVID -[ADDRESS_506390] between participants  and non -clinical personnel. The current epi[INVESTIGATOR_401592]’s LAR. The LAR is lik ely to have been 
exposed to the participant  and may therefore be under self -quarantine at the time of the informed 
consent discussion. Therefore, in addition to the traditional approach of an in -person consent 
discussion and signed paper informed consent, we will allow use of “no -touch” consent 
procedures.  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506391] preference will be to use the FDA COVID MyStudies App platform to obtain informed 
consent via iPads or smartphones securely from participants or LAR  in accordance with 21 CFR 
50.27(a) . Once the  participant or representative has signed the form, he or she will receive an 
electronic copy. The study team will then access the signed consent in a secure manner and print 
it or transfer the file electronically.   
 
If this approach is not possible (e.g. , not compatible with the existing phone or computer device), 
the next approach will be providing an unsigned consent form to the patient by a hospi[INVESTIGATOR_401593] . The study team will arrange 
a telephone call with the participant to review the informed consent document and to obtain 
verbal confirmation by [CONTACT_401664], that they would 
like to participate in the trial, and that they have signed and dated the informed consent 
document that is in their possession. The consent form will document the method used for 
communication with the prospective subject and the specific means by [CONTACT_401665]. An impartial third party will witness 
the entire consent process and sign the consent document. If a participant is unable to provide 
consent on their own behalf, then the study team will obtain consent from a LAR and verbal 
consent with a witness wil l be obtained with appropriate documentation as described above. 
Finally, the participant, the hospi[INVESTIGATOR_401594] a photograph of the signed 
informed consent document. The study team enters the photograph into the trial records and 
document s the consent process in the source document. If it is not possible to obtain a digital 
image of the signed page, the study team will document that the participant signed and dated the 
ICF, document that an imaging device was not available; and have a witn ess to the consent 
process. The entire consent process will be documented in the study records. .   
 
Attestation of informed consent  
If none of the options outlined above (traditional signature [CONTACT_191707] a paper consent form, 
electronic photographs of  a signed consent page, or e -consent) are available, study personnel 
may attest to completion of the informed consent process using the procedures outlined below. 
Importantly, the process of informed consent using this attestation option should not change 
compared with the traditional method of o btaining informed consent for trial participation except 
for the method of documenting the consent process in the research record. Rather than storing a 
paper document with the participant’s signature, a member of the research team and an impartial 
witness  will attest to completion of the informed consent process and that the participant signed 
the informed consent document. This option of attestation of informed consent will not be 
available when obtaining consent through an LAR.  
10.1.2  STUDY DISCONTINUATION AND  CLOSURE  
 
If the study is prematurely terminated or suspended, the site investigator will promptly inform 
study participants, the sIRB, and the FDA and provide the reason(s) for the termination or 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
59 suspension.  Study participants will be contact[INVESTIGATOR_530], as appli cable, and be informed of changes to 
the study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of effic acy that would warrant stoppi[INVESTIGATOR_007]    
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
 
Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed, and satisfy the sIRB, the FDA  and the NIDDK . 
 
10.1.[ADDRESS_506392] party 
without prior writ ten approval. All research activities will be conducted in as private a setting as 
possible. Participant confidentiality will be maintained when study results are published or 
discussed in conferences.  
 
The representatives of the sIRB, and/or regulatory ag encies may inspect all documents and 
records required to be maintained by [CONTACT_093], including but not limited to, medical 
records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The 
clinical study sites will p ermit access to such records.  
 
All source records including electronic data will be stored in secured systems in accordance with  
institutional policies and federal regulations. The study participant’s contact [CONTACT_401666]. At the end of the study, all 
records will continue to be kept in a secure location for as long a period as dictated by [CONTACT_54455], institutional policies, or regulatory requirements. All collected data i ncluding 
electronic and hard copy source records and hard copi[INVESTIGATOR_401595] . Hard copy 
records will be stored  in a locked cabinet in the principal investigator’s Research Office 
accessible to study coordinator and investigator or other designa ted research staff. The electronic 
records will be saved and stored in an institutional computing server accessible by [CONTACT_401667].     
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506393] the site (including any electronic transmission  
of data) will be identified only by a coded number that is linked to a participant through a code 
key maintained at the clinical site.  
 
10.1.4  FUTURE USE OF STORED SPECIMENS  AND DATA   
 
Data colle cted for this study will be stored and analyzed at the coordinating site principal 
investigator’s laboratory. After the study is completed, the de -identified, archived data will be 
stored on the UTHSA server for the Nephrology Division in a folder specific ally for this project, 
for use by [CONTACT_401668]. Biosamples will be made 
available to non -study investigators via NIH policy guidelines.  
 
Secondary Human Subject Research is defined as the re -use of identifiable  data and/or 
identifiable biospecimens that were collected from the primary study – the NIRVANA study. 
Each specimen will be labeled only with a barcode and a unique tracking number to protect 
participant  confidentiality. Secondary research with coded specimens and data may occur; 
however, participant confidentiality will be maintained.  
 
A participant’s decision can be changed at any time by [CONTACT_401669]. If 
the participant subsequently changes his/her decision, the samples will be destroyed if the 
specimens have already not been used for research or released for a specific research project.  
 
All data collected in this study will follow NIH Data Sharing Polices. Data from this study may 
be used for secondary research.  All of the individual participant data collected during the study 
will be made available after de -identification. The investigator may request removal of data on 
individual study participants from NIH data repositories in the event that a research partici pant 
withdraws or changes his or her consent. However, some data that have already been distributed 
for approved research use cannot be revoked or retrieved.  
 
10.1.5  KEY ROLES  AND STUDY GOVERNANCE  
 
Principal Investigator/Sponsor  
Kumar Sharma, MD  
University of T exas Health San Antonio -Department of Nephrology  
[ADDRESS_506394], San Antonio, [LOCATION_007] [ZIP_CODE]  
[PHONE_8324]                                       [EMAIL_7691]  
 
The Steering Committee will consist of the PI’s  of each of the study sites . 
 
10.1.6  SAFETY OVERSIGHT  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
61 Safety oversight will be under the direction of the DSMB. The SAC will adjudicate all reportabl e 
AEs (including SAEs) using supporting documents. The unexpecte d AEs and SAEs will be 
reported to the SAC who wi ll determine if the DSMB will need to evaluate for unblinding.  To 
avoid bias, SAC member will be masked to the study arm of a participant. Adjudicators will 
receive training on the adjudication process.  
Once data are submitted for a participant, the datab ase will notify SAC member that data are 
available and require AE review. SAC member will either confirm or refute the initial 
assessment reported by [CONTACT_401670] . If discrepancies 
occur between the assessments, th e disagreements will be adjudicated on a weekly adjudication 
call with the site investigator and the site SAC member. If disagreement persists, the site 
investigators and the SAC members will formally meet to discuss the event and come to a 
consensus decis ion. All SAEs will trigger immediate notification to the site investigator , site 
SAC member, DCC staff , and the statistician.  
 
There will not be any formal clinical site monitoring for conduct of the site activities. However, 
institutional IRB and Human Subject Protection Committee or institutional compliance may  
perform auditing according to local procedures to ensure that the conduct of the trial is in 
compliance with the currently approved protocol/amendment(s), with International Conference 
on Harmonisation Good Clinical Practice (ICH GCP), and with applicable regulatory 
requirement(s).  
 
Safety oversight will be under the direction of a Data and Safety Monitoring Board (DSMB) 
formed and appointed by [CONTACT_49010]/NIH. Details of the NIDDK policies r egarding DSMBs can 
be found at the following URL https://www.niddk.nih.gov/research -funding/human -subjects -
research/ policies -clinical -researchers/data -safety -monitoring -plans .  Members of the DSMB 
will remain independent from the study conduct and free of conflict of interest. The DSMB will 
provide its input to the steering committee a nd NIDDK , and any relevant safety findings will be 
reported to NIDDK, the FDA and to the sIRB.   
 
10.1.[ADDRESS_506395] of the trial is in compliance with the currently approved protocol/amendment(s), 
with International Conference on Harmonisation Good Clinical Practice (ICH GCP), and with 
applicable regulatory requirement(s).  In these weekly meetings, site investigator will review the 
regulatory files, accountability records, eCRFs, ICFs, medical and laboratory reports, training 
records, and protocol and GCP compliance.  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
62 The local IRB may monitor and audit or otherwise superv ise the study activities. Institutionally 
provided regulatory auditing by [CONTACT_401671]’s human protection office as well as 
applicable oversight committees may occur after enrollment of the first participant  and at least 
once a year until the study is completed. In addition, respective site’s Research and Compliance 
office or equivalent (e.g., Human Research Protection Program) may conduct random or for 
cause audits of the study and report any findings to the  respective IRB. These roles and 
responsibilities of the local IRB will be explicit in the authorization agreement with sIRB .  
 
10.1.[ADDRESS_506396]  KEEPI[INVESTIGATOR_1645]   
  
[IP_ADDRESS]  DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
The clinical site will perform internal quality management of study conduct, data and biological 
specimen collection, documentation and completion.  An individualized quality management 
plan will be developed to describe a site’s quality management.  
 
Quality control (QC) procedures will  be implemented beginning with the REDCap data entry 
system and data checks for missing, out of range and logically inconsistent data values that will 
be run on the database. The Principal Investigator [INVESTIGATOR_401596].  
 
All sites will maintain written Standard Operating Procedures (SOPs) covering study activities. 
The site principal investigator [INVESTIGATOR_401597], data generation, and 
biological specimen collection, documentation and recording, storing, and reporting are in 
compliance with the protocol, International Conference on Harmonisation Good Clinical Practice 
(ICH GCP), and applicable regulatory req uirements (e.g., Good Laboratory Practices (GLP), 
Good Manufacturing Practices (GMP).  
 
All study personnel at three recruiting sites will be trained on study protocol including (i) 
participant screening methods and techniques, (ii) eligibility determinati on, (iii) consenting 
process, (iv) completion of each study visit procedures, (v) data collection, entry, and reporting, 
(vi) biospecimen collection and processing, and storage via Webinar and PowerPoint slides using 
Zoom or other audiovisual methods for c onsistency and harmonization. The DCC , in 
collaboration with two other sites, will prepare the MOP to ensure consistency in protocol 
implementation from study activation/inception until closure and data collection across 
participants and study sites. The M OP will be developed by [CONTACT_401672]. All sites will strictly adhere to the MOP to maintain scientific credibility and provide 
reassurance that participant safety and scientific integrity are closely monitored. The MOP for 
the N IRVANA protocol will contain details of the study’s conduct and operations including (i) 
study’s organization, (ii) operational data definitions, (iii) recruitment, (iv) screening, (v) 
enrollment, (vi) randomization, (vii) follow -up procedures, (viii) data  collection methods, data 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
63 flow, eCRFs, and (ix) guidelines for site -level quality control procedures. The MOP will be 
amended in a timely manner to reflect any amendment to the protocol.  
 
The DCC will determine site activation (shipment of study supplies)  based on successful 
completion of training, a signed site agreement, and a successful study activation web -meeting. 
The investigational site will provide direct access to all trial related sites, source data/documents, 
and reports for the purpose of audit ing and inspection by [CONTACT_3482].  
 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of 
the site investigator. Each local site principal investigator [INVESTIGATOR_401598] e 
source documentation. All source documents will be completed in an ALCOA (Attributable, 
Legible, Contemporaneous, Original and Accurate) legible manner to ensure accurate 
interpretation of data.   
 
Sites will follow Good Documentation Practices f or all study documentation. Each site will 
maintain a local (site) Trial Master File. This is sometimes referred to as site “regulatory 
documents”. The DCC will maintain a TMF for DCC trial documentation originating at the 
DCC. Each site will create and mai ntain source documents as defined in ICH E6 R2 for each 
participant.  
 
The DCC will draft a formal Data Management Plan that specifies all operations performed on 
data from study data acquisition through database lock when no further changes to data are 
allowed. The majority of the Data Management Plan will be accomplished through  a web -based 
Electronic Data Capture (EDC) system for the study developed using REDCap. Sites will be 
trained on use of the study database including screening log completion, data e ntry, independent 
Source Document Verification for point estimation of the medical record abstraction error rate, 
responding to identified data discrepancies, biosample tracking, CTCAE classification and 
grading,  and the SAC event review and adjudication p rocess es. Study -specific procedural 
documentation for these processes will be provided in the MOP.  
 
REDCap Study Database : The REDCap database for the NIRVANA study will be developed 
and maintained by [CONTACT_15791] . Access to the REDCap data system will be  granted to individuals 
upon completion of training. Accessing the REDCap study database will require a user account 
with permissions on the study. A user -maintained password will be entered to log  into the 
system. All study data will be entered by [CONTACT_401673]. To the extent of 
the REDCap system capabilities, upon entry data quality checks for missing, out of range and 
logically inconsistent values will be run. These checks s hould be resolved by [CONTACT_401674]. Because REDCap has limitations with respect to rule -based identification and tracking of 
data discrepancies, comprehensive discrepancy identification and tracking will be performed 
through the Informatics Data Exchange and Acquisition System (IDEAS). Complex checks not 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
64 possible in REDCap will be accomplished through the IDEAS system. Where noted below, 
workflows will be automated based on data collected in the REDCap database.  Study data will 
be accessible to s ites from the REDCap system.  
 
Screening Log : All potential participants for which EHR screening is performed will be entered 
in a de -identified manner on the site screening on REDCap. At the time of entry into the 
screening database the participants will b e assigned a screening number. The screening log will 
capture inclusion and exclusion criteria leading to the site determination of “ineligible”. 
Additionally, the screening log will cover the period between screening and enrollment. As such, 
the screening  log will also document the reason/s “eligible” potential participants were not 
enrolled. The screening log will not contain dates or other information considered identifiable 
health information. The screening log will contain de -identified data elements t hat may be used 
to compare enrolled and non -enrolled participants to assess generalizability.  
 
Clinical Data:  Clinical data from the EHR (includin g AEs, concomitant medications, and 
expected adverse reactions data) and clinical laboratory data will be ente red into the REDCap 
study database .  
 
Adverse Events and Serious Adverse Events : Reportabl e AEs will be entered into the 
REDCap study database. Reportabl e AEs will be entered, classified , and graded according to the 
most current versions of the CTCAE by [CONTACT_3433] e site investigator and independent site SAC 
Physician. Adverse events indicated as Serious Adverse Events will result in real -time alerts 
through the REDCap system to support expedited reporting. Entry of reportable Adverse Events 
will trigger notificatio n to the independent SAC physician to initiate the independent review and 
adjudication process as described in section 8.3.7 . AEs will be coded at the DCC  using the 
MedDRA controlled terminology.  
Biosample Inventory and Tracking : The REDCap study database  will include screens at each 
visit for sites to report samples obtained and shipped to the UTHSA COVID -19 Repository. 
Sample tracking will trigger notification to the repository. Samples received will be reconciled 
with REDCap biosample tracking on the da y of receipt. Data status reports will flag expected 
and missing sample tracking data.  
 
Data Status Reports : Enrollment  data will be entered into REDCap on the day of enrollment. 
Enrollment entry enables tracking and management of participant data and samples and will 
trigger notification to the site and DCC  study team. Data entry will be entered every day during 
the 10 -day treatment pe riod and within one week of follow -up visits. Late data will be listed on 
an exception report by [CONTACT_401675] t. Similarly, data discrepancies will be resolved 
within a week of firing. Late data discrepancy resolutions will be listed on an excepti on report by 
[CONTACT_401676]. Data will be reviewed by [CONTACT_401677] 24 hours of complete entry . 
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
65 The site investigator will be responsible for review of data collection tools and processes, and 
review of data and reports.  
 
 
 
[IP_ADDRESS]  STUDY RECORDS RETENTION  
 
Study related records, including the regulatory file, study product accountability records, consent  
forms, participant’s  source documents and electronic records should be maintained for a period 
no shorter than [ADDRESS_506397]  research.  Local 
institutional and applicable NIH policies will be adhered to and records  will be  retained 
according to whichever policy dictates a longer period in order to remain compli ant with 
retention policies.  
 
10.1.9  PROTOCOL DEVIATIONS  
 
A protocol deviation  is any change, divergence, or departure from the study design or procedures 
defined in the protocol.  
 
Major Deviation: Major protocol deviations  are a subset of protocol deviations t hat might 
significantly affect the completeness, accuracy, and/or reliability of the study data or that might 
significantly affect a participant s’ rights, safety, or well -being. Examples may include:  
  
• Enrolling participants who did not meet eligibility criteria  
• Performing study procedures before obtaining informed consent  
• Failure to obtain and/or document informed consent  
• Failing  to follow protocol procedures that specifically relate to the primary s afety or 
efficacy endpoints of the study  
 
Minor Deviation: Minor protocol deviations  are a subset of protocol deviations that do not have 
a major impact on either the participant’s rights, safety or well -being, or the completeness, 
accuracy and reliability  of the study data. Examples may include:  
• Follow up visits occurring outside the protocol required time frame because of the 
participant was not available or other restrictions;  
• Blood samples being obtained at times close to but not precisely at the time points 
specified in the protocol.  
 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
66 All protocol deviations will be entered on the Protocol Deviation Log in REDCap and submitted 
to the sIRB as well as respective site’s IRB per their policies. All major deviations will be 
promptly submitted to sIRB and local IRB.  Site will also submit all protocol deviations to 
DSMB as per DSMB guidelines. The site investigator is responsible for knowing and adhering to 
the sIRB and DSMB req uirements.  
10.1.[ADDRESS_506398]  POLICY  
 
The independence of this study from any actual or perceived influence, such as by [CONTACT_401678] (ChromaDex), is critical. Therefore, any actual conflict of interest of 
persons who have a role in the design, conduct, analysis, publication, or an y aspect of this trial 
will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest 
will be required to have such conflicts managed in a way that is appropriate to their participation 
in the design and conduct of this trial . 
 
10.2 ADDITIONAL CONSIDERATIONS  
  
 
Not applicable.  
 
  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
[ADDRESS_506399] Operating Procedure  
UP Unanticipated Problem  
 
  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
68 10.4 PROTOCOL  AMENDMENT  HISTORY  
  
Version  Date  Description of Change   Brief Rationale  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
 
  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
69 11 REFERENCES  
 
[1] Brooks C, Wei Q, Cho S, Dong Z: Regulation of mitochondrial dynamics in acute kidney 
injury in cell culture and rodent models. J Clin Invest 2009;119(5):1275 -1285 DOI: 
10.1172/JCI37829.  
[2] Che R, Yuan Y, Huang S, Zhang A: Mitochondrial dysfunction in the pathophysiology of 
renal diseases. Am J Physio l Renal Physiol 2014;306(4):367 DOI: 
10.1152/ajprenal.[ZIP_CODE].2013.  
[3] Emma F, Montini G, Parikh SM, Salviati L: Mitochondrial dysfunction in inherited renal 
disease and acute kidney injury. Nat Rev Nephrol 2016;12(5):267 -280 DOI: 
10.1038/nrneph.2015.214.  
[4] Tran MT, Zsengeller ZK, Berg AH, Khankin EV, Bhasin MK, Kim W, Clish CB, Stillman 
IE, Karumanchi SA, Rhee EP, Parikh SM: PGC1α drives NAD biosynthesis linking 
oxidative metabolism to renal protection. Nature 2016;531(7595):528 -532 DOI: 
10.1038/nature171 84. 
[5] Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J, Lerner A, Kher A, 
Kim SH, Khoury CC, Herzig SJ, Trovato ME, Simon -Tillaux N, Lynch MR, Thadhani RI, 
Clish CB, Khabbaz KR, Rhee EP, Waikar SS, Berg AH, Parikh SM: De novo NAD+ 
biosynthet ic impairment in acute kidney injury in humans. Nat Med 2018;24(9):1351 -1359 
DOI: 10.1038/s41591 -018-0138 -z. 
[6] Funk JA, Schnellmann RG: Persistent disruption of mitochondrial homeostasis after acute 
kidney injury. Am J Physiol Renal Physiol 2012;302(7):853 DOI: 
10.1152/ajprenal.[ZIP_CODE].2011.  
[7] Martens CR, Denman BA, Mazzo MR, Armstrong ML, Reisdorph N, McQueen MB, 
Chonchol M, Seals DR: Chronic  nicotinamide riboside supplementation is well -tolerated 
and elevates NAD+ in healthy middle -aged and  older adults. Nat Commun 2018;9(1):1286 
DOI: 10.1038/s41467 -018-[ZIP_CODE] -7. 
[8] Conze D, Brenner C, Kruger CL: Safety and Metabolism of Long -term Administration of 
NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double -Blind, Placebo -
controlled Clin ical Trial of Healthy Overweight Adults. Sci Rep 2019;9(1):9772 DOI: 
10.1038/s41598 -019-[ZIP_CODE] -z. 
[9] Toropova YG, Pechnikova NA, Zelinskaya IA, Zhuravsky SG, Kornyushin OV, Gonchar AI, 
Ivkin DY, Leonova YV, Karev VE, Karabak IA: Nicotinamide riboside has p rotective 
effects in a rat model of mesenteric ischaemia -reperfusion. Int J Exp Pathol 2018;99(6):304 -
311 DOI: 10.1111/iep.[ZIP_CODE].  
[10] Diguet N, Trammell SAJ, Tannous C, Deloux R, Pi[INVESTIGATOR_401599] J, Mougenot N, Gouge A, 
Gressette M, Manoury B, Blanc J, Breton M,  Decaux J, Lavery GG, Baczkó I, Zoll J, 
Garnier A, Li Z, Brenner C, Mericskay M: Nicotinamide Riboside Preserves Cardiac 
Function in a Mouse Model of Dilated Cardiomyopathy. Circulation 2018;137(21):2256 -
2273 DOI: 10.1161/CIRCULATIONAHA.116.026099.  
[11] Do llerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde -
Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N: A randomized placebo -controlled 
clinical trial of nicotinamide riboside in obese men: safety, insulin -sensitivity, and li pid-
mobilizing effects. Am J Clin Nutr 2018;108(2):343 -353 DOI: 10.1093/ajcn/nqy132.  
[12] Giroud -Gerbetant J, Joffraud M, Giner MP, Cercillieux A, Bartova S, Makarov MV, 
Zapata -Pérez R, Sánchez -García JL, Houtkooper RH, Migaud ME, Moco S, Canto C: A 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
70 reduce d form of nicotinamide riboside defines a new path for NAD+ biosynthesis and acts 
as an orally bioavailable NAD+ precursor. Mol Metab 2019;30:192 -202 DOI: 
10.1016/j.molmet.2019.09.013.  
[13] Dolopi[INVESTIGATOR_401600], Kourtzidis IA, Margaritelis NV, Vrabas IS, Koidou I,  Kyparos A, 
Theodorou AA, Paschalis V, Nikolaidis MG: Acute nicotinamide riboside supplementation 
improves redox homeostasis and exercise performance in old individuals: a double -blind 
cross -over study. Eur J Nutr 2020;59(2):505 -515 DOI: 10.1007/s00394 -019-[ZIP_CODE] -4. 
[14] Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, 
Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai Y, 
Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery 
GG: Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ 
Metabolome and Induces Transcriptomic and Anti -inflammatory Signatures. Cell Rep 
2019;28(7):1717 -1728.e6 DOI: 10.1016/j.celrep.2019.07.043.  
[15] Simic P, Vela Parada XF, Parik h SM, Dellinger R, Guarente LP, Rhee EP: Nicotinamide 
riboside with pterostilbene (NRPT) increases NAD+ in patients with acute kidney injury 
(AKI): a randomized, double -blind, placebo -controlled, stepwise safety study of escalating 
doses of NRPT in patient s with AKI. BMC Nephrol 2020;21(1):342 DOI: 10.1186/s12882 -
020-[ZIP_CODE] -1. 
[16] Stein LR, Imai S: The dynamic regulation of NAD metabolism in mitochondria. Trends 
Endocrinol Metab 2012;23(9):420 -428 DOI: 10.1016/j.tem.2012.06.005.  
[17] Keefe DM: Agency Respon se Letter GRAS Notice No. GRN 000635.  
[18] Weiss P, Murdoch DR: Clinical course and mortality risk of severe COVID -19. Lancet 
2020;395([ZIP_CODE]):1014 -1015 DOI: 10.1016/S0140 -6736(20)[ZIP_CODE] -4. 
[19] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu 
T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang 
G, Jiang R, Gao Z, Jin Q, Wang J, Cao B: Clinical features of patients infected with 2019 
novel coronavirus in Wuhan, China. Lancet 2020;395([ZIP_CODE]):497 -506 DOI: 
10.1016/S0140 -6736(20)[ZIP_CODE] -5. 
[20] Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, 
Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q: Clinical 
characteristics of 113 deceased patients with  coronavirus disease 2019: retrospective study. 
BMJ 2020;368:m1091 DOI: 10.1136/bmj.m1091.  
[21] Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, Shan H, Lei C, Hui DSC, Du B, Li L, 
Zeng G, Yuen K, Chen R, Tang C, Wang T, Chen P, Xiang J, Li S, Wang J, Liang  Z, Peng 
Y, Wei L, Liu Y, Hu Y, Peng P, Wang J, Liu J, Chen Z, Li G, Zheng Z, Qiu S, Luo J, Ye C, 
Zhu S, Zhong N: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J 
Med 2020;382(18):1708 -1720 DOI: 10.1056/NEJMoa2002032.  
[22] Pei G, Zha ng Z, Peng J, Liu L, Zhang C, Yu C, Ma Z, Huang Y, Liu W, Yao Y, Zeng R, Xu 
G: Renal Involvement and Early Prognosis in Patients with COVID -19 Pneumonia. J Am 
Soc Nephrol 2020 DOI: 10.1681/ASN.[PHONE_8325].  
[23] Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, Hazzan AD, Fishbane S, 
Jhaveri KD: ACUTE KIDNEY INJURY IN PATIENTS HOSPI[INVESTIGATOR_401601] -
19. Kidney Int 2020 DOI: 10.1016/j.kint.2020.05.006.  
[24] Lili Chan, Kumardeep Chaudhary, Aparna Saha, et al: Acute Kidney Injury in Hospi[INVESTIGATOR_401602] s with COVID -19. doi.org/10.1101/2020.05.04.20090944.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
71 [25] Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B, Petrilli CM: Trends in 
COVID -19 Risk -Adjusted Mortality Rates. J Hosp Med 2020 DOI: 10.[ZIP_CODE]/jhm.3552.  
[26] Agarwal A, Dong Z, Harris  R, Murray P, Parikh SM, Rosner MH, Kellum JA, Ronco C: 
Cellular and Molecular Mechanisms of AKI. J Am Soc Nephrol 2016;27(5):1288 -1299 
DOI: 10.1681/ASN.[PHONE_8326].  
[27] Alge JL, Arthur JM: Biomarkers of AKI: a review of mechanistic relevance and potential  
therapeutic implications. Clin J Am Soc Nephrol 2015;10(1):147 -155 DOI: 
10.2215/CJN.12191213.  
[28] Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S: 
Acute Kidney Injury in COVID -19: Emerging Evidence of a Distinct Pathophysio logy. J 
Am Soc Nephrol 2020 DOI: 10.1681/ASN.[PHONE_8327].  
[29] Moore JB, June CH: Cytokine release syndrome in severe COVID -19. Science 
2020;368(6490):473 -474 DOI: 10.1126/science.abb8925.  
[30] Farkash EA, Wilson AM, Jentzen JM: Ultrastructural Evidence for  Direct Renal Infection 
with SARS -CoV -2. J Am Soc Nephrol 2020 DOI: 10.1681/ASN.[PHONE_8328].  
[31] Su H, Yang M, Wan C, Yi L, Tang F, Zhu H, Yi F, Yang H, Fogo AB, Nie X, Zhang C: 
Renal histopathological analysis of 26 postmortem findings of patients with CO VID-19 in 
China. Kidney Int 2020 DOI: 10.1016/j.kint.2020.04.003.  
[32] Trammell SAJ, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, 
Abel ED, Migaud ME, Brenner C: Nicotinamide riboside is uniquely and orally bioavailable 
in mice and hum ans. Nat Commun 2016;7:[ZIP_CODE] DOI: 10.1038/ncomms12948.  
[33] Cantó C, Houtkooper RH, Pi[INVESTIGATOR_140486] E, Youn DY, Oosterveer MH, Cen Y, Fernandez -Marcos 
PJ, Yamamoto H, Andreux PA, Cettour -Rose P, Gademann K, Rinsch C, Schoonjans K, 
Sauve AA, Auwerx J: The NAD(+) pr ecursor nicotinamide riboside enhances oxidative 
metabolism and protects against high -fat diet -induced obesity. Cell Metab 2012;15(6):838 -
847 DOI: 10.1016/j.cmet.2012.04.022.  
[34] Wang S, Wan T, Ye M, Qiu Y, Pei L, Jiang R, Pang N, Huang Y, Liang B, Ling W, Lin X, 
Zhang Z, Yang L: Nicotinamide riboside attenuates alcohol induced liver injuries via 
activation of SirT1/PGC -1α/mitochondrial biosynthesis pathway. Redox Biol 2018;17:89 -98 
DOI: 10.1016/j.redox.2018.04.006.  
[35] Gariani K, Menzies KJ, Ryu D,  Wegner CJ, Wang X, Ropelle ER, Moullan N, Zhang H, 
Perino A, Lemos V, Kim B, Park Y, Pi[INVESTIGATOR_79406] A, Pham TX, Yang Y, Ku CS, Koo SI, 
Fomitchova A, Cantó C, Schoonjans K, Sauve AA, Lee J, Auwerx J: Eliciting the 
mitochondrial unfolded protein response by [CONTACT_401679]. Hepatology 2016;63(4):1190 -1204 DOI: 
10.1002/hep.[ZIP_CODE].  
[36] Sambeat A, Ratajczak J, Joffraud M, Sanchez -Garcia JL, Giner MP, Valsesia A, Giroud -
Gerbetant J, Valera -Alberni M, Cercillieux A, Boutant M, Kulkarni SS, Moco S, Canto C: 
Endogenous nicotinamide riboside metabolism protects against diet -induced liver damage. 
Nat Commun 2019;10(1):4291 DOI: 10.1038/s41467 -019-[ZIP_CODE] -x. 
[37] Chi Y, Sauve AA: Nicotinamide riboside, a trace  nutrient in foods, is a vitamin B3 with 
effects on energy metabolism and neuroprotection. Curr Opin Clin Nutr Metab Care 
2013;16(6):657 -661 DOI: 10.1097/MCO.0b013e32836510c0.  
[38] Airhart SE, Shireman LM, Risler LJ, Anderson GD, Nagana Gowda GA, Raftery D , Tian R, 
Shen DD, O'Brien KD: An open -label, non -randomized study of the pharmacokinetics of the 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
72 nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in 
healthy volunteers. PLoS ONE 2017;12(12):e0186459 DOI: 10.1371/journ al.pone.0186459.  
[39] Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde -
Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N: A randomized placebo -controlled 
clinical trial of nicotinamide riboside in obese men: safety, ins ulin-sensitivity, and lipid -
mobilizing effects. Am J Clin Nutr 2018;108(2):343 -353 DOI: 10.1093/ajcn/nqy132.  
[40] Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E: 
Repeat dose NRPT (nicotinamide riboside and pterostilbene) i ncreases NAD+ levels in 
humans safely and sustainably: a randomized, double -blind, placebo -controlled study. NPJ 
Aging Mech Dis 2017;3:17 DOI: 10.1038/s41514 -017-0016 -9. 
[41] Anonymous Clinicaltrials.gov: Nicotinamide Riboside Supplementation for Treating 
Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe 
CKD. Available at 
https://clinicaltrials.gov/ct 2/show/[STUDY_ID_REMOVED]?cond=NICOTINAMIDE+RIBOSIDE&dra
w=3&rank=18  . 
[42] Anonymous Clinicaltrials.gov: Trial of Nicotinamide Riboside and Co -enzyme Q10 in 
Chronic Kidney Disease (CoNR). Available at 
https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED]?cond=NICOTINAMIDE+RIBOSIDE&dra
w=5&rank=11  . 
[43] Rennick A, Kalakeche R, Seel L, Shepler B: Nicotinic acid and nicotinamide: a review of 
their use for hyperphosphatemia in dialysis patients. Pharmacotherapy 2013;33(6):683 -690 
DOI: 10.1002/phar.1258.  
[44] Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, 
Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M: Effects of Nicotinamide and 
Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor -23 in CKD: The 
COMBINE Trial. J Am Soc Nephrol 2019;30(6):1096 -1108 DOI: 
10.1681/ASN.[PHONE_8329].  
[45] Sh ahbazian H, Zafar Mohtashami A, Ghorbani A, Abbaspour MR, Belladi Musavi SS, 
Hayati F, Lashkarara GR: Oral nicotinamide reduces serum phosphorus, increases HDL, and 
induces thrombocytopenia in hemodialysis patients: a double -blind randomized clinical trial . 
Nefrologia 2011;31(1):58 -65 DOI: 10.3265/Nefrologia.pre2010.Nov.[ZIP_CODE].  
[46] Lenglet A, Liabeuf S, El Esper N, Brisset S, Mansour J, Lemaire -Hurtel A, Mary A, Brazier 
M, Kamel S, Mentaverri R, Choukroun G, Fournier A, Massy ZA: Efficacy and safety of 
nicotinamide in haemodialysis patients: the NICOREN study. Nephrol Dial Transplant 
2017;32(5):870 -879 DOI: 10.1093/ndt/gfw042.  
[47] Young DO, Cheng SC, Delmez JA, Coyne DW: The effect of oral niacinamide on plasma 
phosphorus levels in peritoneal dialysis patie nts. Perit Dial Int 2009;29(5):562 -567. 
[48] Elhassan YS, Philp AA, Lavery GG: Targeting NAD+ in Metabolic Disease: New Insights 
Into an Old Molecule. J Endocr Soc 2017;1(7):816 -835 DOI: 10.1210/js.2017 -[ZIP_CODE].  
[49] El Borolossy R, El Wakeel LM, El Hakim I,  Sabri N: Efficacy and safety of nicotinamide in 
the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr 
Nephrol 2016;31(2):289 -296 DOI: 10.1007/s00467 -015-3208 -1. 
[50] Lenglet A, Liabeuf S, Bodeau S, Louvet L, Mary A, Bo ullier A, Lemaire -Hurtel AS, Jonet 
A, Sonnet P, Kamel S, Massy ZA: N -methyl -2-pyridone -5-carboxamide (2PY) -Major 
Metabolite of Nicotinamide: An Update on an Old Uremic Toxin. Toxins (Basel) 
2016;8(11) DOI: 10.3390/toxins8110339.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
73 [51] Rutkowski B, Slominska  E, Szolkiewicz M, Smolenski RT, Striley C, Rutkowski P, 
Swierczynski J: N -methyl -2-pyridone -5-carboxamide: a novel uremic toxin?. Kidney Int 
Suppl 2003(84):19 DOI: 10.1046/j.1523 -1755.63.s84.36.x.  
[52] Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shib ata K, Shimada N, Ebihara I, 
Koide H: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 
2004;65(3):1099 -1104 DOI: 10.1111/j.1523 -1755.2004.[ZIP_CODE].x.  
[53] Rutkowski B, Rutkowski P, Słomińska E, Smolenski RT, Swierczyński J: Cellu lar toxicity 
of nicotinamide metabolites. J Ren Nutr 2012;22(1):95 -97 DOI: 10.1053/j.jrn.2011.10.033.  
[54] Gale EaM, Bingley PJ, Emmett CL, Collier T: European Nicotinamide Diabetes 
Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of 
type 1 diabetes. Lancet 2004;363(9413):925 -931 DOI: 10.1016/S0140 -6736(04)[ZIP_CODE] -3. 
[55] Reiche I, Westphal S, Martens -Lobenhoffer J, Tröger U, Luley C, Bode -Böger SM: 
Pharmacokinetics and dose recommendations of Niaspan® in chronic kidn ey disease and 
dialysis patients. Nephrol Dial Transplant 2011;26(1):276 -282 DOI: 10.1093/ndt/gfq344.  
[56] Lenglet A, Liabeuf S, Guffroy P, Fournier A, Brazier M, Massy ZA: Use of nicotinamide to 
treat hyperphosphatemia in dialysis patients. Drugs R D 2013 ;13(3):165 -173 DOI: 
10.1007/s40268 -013-0024 -6. 
[57] Dodd LE, Follmann D, Wang J, Koenig F, Korn LL, Schoergenhofer C, Proschan M, 
Hunsberger S, Bonnett T, Makowski M, Belhadi D, Wang Y, Cao B, Mentre F, Jaki T: 
Endpoints for randomized controlled clinical trials for COVID -19 treatments. Clin Trials 
2020;17(5):472 -482 DOI: 10.1177/1740774520939938.  
[58] Anonymous A minimal common outcome measure set for COVID -[ADDRESS_506400] Dis 2020;20(8):e192 -e197 DOI: 10.1016/S1473 -3099(20)[ZIP_CODE] -7. 
[59] Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G: Kidney 
disease is associated with in -hospi[INVESTIGATOR_45084] -19. Kidney Int 
2020;97(5):829 -838 DOI: 10.1016/j.kint.2020.03.005.  
[60] Durvasula R, Wellington T, McNama ra E, Watnick S: COVID -19 and Kidney Failure in the 
Acute Care Setting: Our Experience From Seattle. Am J Kidney Dis 2020 DOI: 
10.1053/j.ajkd.2020.04.001.  
[61] Ronco C, Reis T: Kidney involvement in COVID -19 and rationale for extracorporeal 
therapi[INVESTIGATOR_014]. Nat Rev Nephrol 2020 DOI: 10.1038/s41581 -020-0284 -7. 
[62] Wang X, Xu W, Hu G, Xia S, Sun Z, Liu Z, Xie Y, Zhang R, Jiang S, Lu L: SARS -CoV -2 
infects T lymphocytes through its spi[INVESTIGATOR_144870] -mediated membrane fusion. Cell Mol 
Immunol 2020 DOI: 10.1038/s41423 -020-0424 -9. 
[63] Zhang C, Wu Z, Li J, Zhao H, Wang G: Cytokine release syndrome in severe COVID -19: 
interleukin -[ADDRESS_506401] tocilizumab may be the key to reduce mortality. Int J 
Antimicrob Agents 2020;55(5):105954 DOI: 10.1016/j.ij antimicag.2020.105954.  
[64] Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan 
A, Wei H: Effective treatment of severe COVID -19 patients with tocilizumab. Proc Natl 
Acad Sci U S A 2020;117(20):[ZIP_CODE] -[ZIP_CODE] DOI: 10.1073/pnas. [PHONE_8330].  
[65] Batlle D, Wysocki J, Satchell K: Soluble angiotensin -converting enzyme 2: a potential 
approach for coronavirus infection therapy?. Clin Sci 2020;134(5):543 -545 DOI: 
10.1042/CS20200163.  
[66] Khan A, Benthin C, Zeno B, Albertson TE, Boyd J, Christie JD, Hall R, Poirier G, Ronco 
JJ, Tidswell M, Hardes K, Powley WM, Wright TJ, Siederer SK, Fairman DA, Lipson DA, 
Bayliffe AI, Lazaar AL: A pi[INVESTIGATOR_191627] -converting 
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
74 enzyme 2 in acute respi[INVESTIGATOR_138711]. Crit Care 2017;21(1):234 DOI: 
10.1186/s13054 -017-1823 -x. 
[67] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, 
Luzuriaga K, Greenough TC, Choe H, Farzan M: Angiotensin -converting enzyme 2 is a 
functional receptor fo r the SARS coronavirus. Nature 2003;426(6965):450 -454 DOI: 
10.1038/nature02145.  
[68] Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu 
HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, 
Hsieh L,  Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, 
Ohmagari N, Oh M, Ruiz -Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar 
RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green 
M, Makowski M, Os inusi A, Nayak S, Lane HC: Remdesivir for the Treatment of Covid -19 
- Preliminary Report. N Engl J Med 2020 DOI: 10.1056/NEJMoa2007764.  
[69] Willicombe M, Thomas D, McAdoo S: COVID -19 and Calcineurin Inhibitors: Should They 
Get Left Out in the Storm?. J Am  Soc Nephrol 2020 DOI: 10.1681/ASN.[PHONE_8331].  
[70] Anonymous Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, 
Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC), National 
Academies Press (US), 1998.  
[71] Anon ymous Clinicaltrials.gov: Nicotinamide Riboside. Available at 
https://clinicaltrials.gov/ct2/results?cond=NICOTINAMIDE+RIBOSIDE&ter m=&cntry=&
state=&city=&dist=  . 
[72] KDIGO AKI Work Group: KDIGO clinical practice guideline for acute kidney injury.  
2012(Suppl. 17):1 -138. 
[73] Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, Maffei C,  Possenti S, 
Zambetti N, Moscato M, Venturini M, Affatato S, Gaggiotti M, Bossini N, Scolari F: A 
single center observational study of  the clinical characteristics and short -term outcome of 20 
kidney transplant patients admitted for SARS -CoV2 pneumonia. Ki dney Int 
2020;97(6):1083 -1088 DOI: 10.1016/j.kint.2020.04.002.  
[74] Alasfar S, Avery RK: The impact of COVID -19 on kidney transplantation. Nat Rev Nephrol 
2020;16(10):568 -569 DOI: 10.1038/s41581 -020-[ZIP_CODE] -z. 
[75] Chan KH, Farouji I, Abu Hanoud A, Slim J: W eakness and elevated creatinine kinase as the 
initial presentation of coronavirus disease 2019 (COVID -19). Am J Emerg Med 
2020;38(7):1548.e1 -1548.e3 DOI: 10.1016/j.ajem.2020.05.015.  
[76] Jin M, Tong Q: Rhabdomyolysis as Potential Late Complication Associat ed with COVID -
19. Emerg Infect Dis 2020;26(7):1618 -1620 DOI: 10.3201/eid2607.200445.  
[77] Valente -Acosta B, Moreno -Sanchez F, Fueyo -Rodriguez O, Palomar -Lever A: 
Rhabdomyolysis as an initial presentation in a patient diagnosed with COVID -19. BMJ 
Case Rep 2 020;13(6) DOI: 10.1136/bcr -2020 -236719.  
[78] Chedid NR, Udit S, Solhjou Z, Patanwala MY, Sheridan AM, Barkoudah E: COVID -19 and 
Rhabdomyolysis. J Gen Intern Med 2020;35(10):3087 -3090 DOI: 10.1007/s11606 -020-
[ZIP_CODE] -y. 
[79] Suwanwongse K, Shabarek N: Rhabdomy olysis as a Presentation of 2019 Novel 
Coronavirus Disease. Cureus 2020;12(4):e7561 DOI: 10.7759/cureus.7561.  
[80] Taxbro K, Kahlow H, Wulcan H, Fornarve A: Rhabdomyolysis and acute kidney injury in 
severe COVID -19 infection. BMJ Case Rep 2020;13(9) DOI: 1 0.1136/bcr -2020 -237616.  
Nicotinamide Riboside for AKI in COVID -19 positive inpatients  Version XX 
Protocol #: Not yet assigned  <DD Month YYYY>  
75 [81] Han X, Bao X, Lou Q, Xie X, Zhang M, Zhou S, Guo H, Jiang G, Shi Q: Nicotinamide 
riboside exerts protective effect against aging -induced NAFLD -like hepatic dysfunction in 
mice. PeerJ 2019;7:e7568 DOI: 10.7717/peerj.7568.  
[82] A nonymous Food and Drug Administration.  Guidance for Industry  
Drug -Induced Liver Injury: Premarketing Clinical Evaluation.  July 2009.  
[83] Gupta SK: Intention -to-treat concept: A review. Perspect Clin Res 2011;2(3):109 -112 DOI: 
10.4103/2229 -3485.[ZIP_CODE].  
[84] Rubin DB: Multiple Imputation for Nonresponse in Surveys. [LOCATION_001], Wiley, 1987.  
[85] Walker GA, Shostak J: Common Statistical Methods for Clinical Research with SAS 
Examples, ed 3rd. Vary, North Carolina, [LOCATION_003], SAS Institute, 2010.  
[86] Schluchter MD, Gre ene T, Beck GJ. Analysis of change in the presence of informative 
censoring: application to a longitudinal clinical trial of progressive renal disease. Statistics 
in medicine. 2001 Apr 15;20(7):989 -1007 . 
[87] Levey AS, Stevens LA, Schmid CH, Zhang YL, Cast ro AF, Feldman HI, Kusek JW, Eggers 
P, Van Lente F, Greene T, Coresh J: A new equation to estimate glomerular filtration rate. 
Ann Intern Med 2009;150(9):604 -612 DOI: 10.7326/0003 -4819 -150-9-200905050 -[ZIP_CODE].  
  